

# Lichen Depsidones with Biological Interest

## Authors

Isabel Ureña-Vacas, Elena González-Burgos, Pradeep Kumar Divakar, M. Pilar Gómez-Serranillos

## Affiliation

Department of Pharmacology, Pharmacognosy and Botany,  
Faculty of Pharmacy, Complutense University of Madrid  
(Spain)

## Key words

secondary metabolites, natural products, pharmacology,  
antioxidants, antimicrobial, cytotoxic

received March 9, 2021  
accepted after revision April 13, 2021  
published online May 25, 2021

## Bibliography

Planta Med 2022; 88: 855–880

DOI 10.1055/a-1482-6381

ISSN 0032-0943

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG, Rüdigerstraße 14,  
70469 Stuttgart, Germany

## Correspondence

Dr. Elena González Burgos  
Department of Pharmacology, Pharmacognosy and Botany,  
Faculty of Pharmacy, Complutense University of Madrid  
(Spain)  
Plaza Ramón y Cajal s/n, 28040 Madrid, Spain  
Phone: + 34 913 9422 76, Fax: + 34 913 9416 24  
elenagon@ucm.es

## ABSTRACT

Depsidones are some of the most abundant secondary metabolites produced by lichens. These compounds have aroused great pharmacological interest due to their activities as antioxidants, antimicrobial, and cytotoxic agents. Hence, this paper aims to provide up-to-date knowledge including an overview of the potential biological interest of lichen depsidones. So far, the most studied depsidones are fumarprotocetraric acid, lobaric acid, norstictic acid, physodic acid, salazinic acid, and stictic acid. Their pharmacological activities have been mainly investigated in *in vitro* studies and, to a lesser extent, in *in vivo* studies. No clinical trials have been performed yet. Depsidones are promising cytotoxic agents that act against different cell lines of animal and human origin. Moreover, these compounds have shown antimicrobial activity against both Gram-positive and Gram-negative bacteria and fungi, mainly *Candida* spp. Furthermore, depsidones have antioxidant properties as revealed in oxidative stress *in vitro* and *in vivo* models. Future research should be focused on further investigating the mechanism of action of depsidones and in evaluating new potential actions as well as other depsidones that have not been studied yet from a pharmacological perspective. Likewise, more *in vivo* studies are prerequisite, and clinical trials for the most promising depsidones are encouraged.

## Introduction

Lichens are a unique symbiosis between a fungus belonging to Ascomycota and Basidiomycota phylum (mycobiont) and a chlorophyll-containing partner (photobiont), which is an alga or a cyanobacterium. Moreover, recent studies have identified specific bacterial microbiomes as the third component of lichen [1,2]. Lichens have been traditionally used for their medicinal value as healing (i.e., *Heterodermia diademata* [Taylor] D.D. Awasthi) and cold (i.e., *Everniastrum cirrhatum* [Fr.] Hale ex Sipman.), for their culinary value for preparing tea, curry, soup, pickle, and sausages (i.e., *Everniastrum nepalense* [Taylor] Hale ex Sipman; *Cladonia rangiferina* [L.] Weber ex F.H. Wigg.), and for their ritual, spiritual, and aesthetic values (i.e., *Thamnomia vermicularis* [Sw.] Ach. ex Schaer.) [3–5].

Lichens produce unique and diverse secondary metabolites. So far, over 1000 compounds have been identified, including depsi-


done, depsides, dibenzofurans, and xanthenes, which are synthesized via the acetate-malonate pathway, pulvinic acid derivatives formed in the shikimic acid pathway, and terpenes and steroids via the mevalonic acid pathway. The amount of these secondary metabolites may vary from 0.1% to 30% of the dry weight of the thallus, and they are deposited in both the cortex and the medullary layers. Hence, depsides and dibenzofurans, such as usnic acid (major) and atranorin (trace) in *Flavoparmelia caperata* L. (Hale) and atranorin and chloroatranorin in *Hypogymnia physodes* (L.) Nyl., are found in the cortex, whereas depsidones, such as physodic acid, 3-hydroxyphysodic acid, and physodalic acid as major compounds in *H. physodes* (L.) Nyl., norstictic acid in *Parmotrema perforatum* (Jacq.) A. Massal., and salazinic acid (major) and consalazinic acids (minor) in *Parmelia saxatilis* (L.) Ach., are found in the medullary layer [6–9]. These secondary metabolites play a key role in chemotaxonomy and systematics [6]. Moreover, they exert diverse biological functions including protection against

## ABBREVIATIONS

8-OH-dG	8-Oxo-2'-deoxyguanosine
Axin2	axis inhibition protein 2
Bax	Bcl-2 associated X-protein
Bcl-2	B-cell lymphoma 2
BDNF	brain-derived neurotrophic factor
COX	cyclooxygenase
DPPH	2,2-diphenyl-1-picrylhydrazil
FabZ	3-hydroxyacyl-[acyl-carrier-protein] dehydratase
FAS	fatty acid biosynthesis
GSH	reduced glutathione
HGF	hepatocyte growth factor
Hsp70	70 kD heat shock proteins
HSV	herpes simplex virus
IL-1	interleukin-1
JAK/STAT	janus kinase/signal transducers and activators of transcription
LPS	lipopolysaccharide
MAPK	mitogen-activated protein kinases
MIC	minimum inhibitory concentration
MMP7	matrix metalloproteinase-7
MPP1	M-Phase Phosphoprotein 1
MRSA	methicillin-resistant <i>Staphylococcus aureus</i>
NF- $\kappa$ B	nuclear Factor kappa-light-chain-enhancer of activated B cells
NGF	nerve growth factor
NLRP3	NOD-, LRR- and pyrin domain-containing protein 3
NOS	nitric oxide synthase
Nrf2	nuclear factor E2-related factor 2
nsP1	nonstructural protein 1
ORAC	oxygen radical absorbance capacity
PAR2	proteinase-activated receptor-2
PARP	poly (ADP-ribose) polymerase
PF-UVA	protection Factor-ultraviolet A
PI3K	phosphatidylinositol 3-kinase
PKS	polyketide synthase
Plk1	polo-like kinase-1
PTP1B	protein tyrosine phosphatase 1B
RNS	reactive nitrogen species
ROS	reactive oxygen species
SLIGKV-NH <sub>2</sub>	Ser-Leu-Ile-Gly-Lys-Val-amide
SOR	scavenging superoxide radicals
TNF- $\alpha$	tumor necrosis factor- $\alpha$
TRAIL	TNF-related apoptosis-inducing ligand
Trp-P-2	tryptophan pyrolysis product-2

pathogens, herbivores, and UV irradiation [7]. Furthermore, these secondary metabolites of lichens arouse great pharmacological interest due to their activities, mainly as antioxidants, antimicrobials, and cytotoxic agents [10–12].

Some of the most abundant groups of secondary metabolites in lichens are depsidones (around 100) [13]. Structurally, depsi-



► Fig. 1 General structure of depsidones.

ones consist of a polycyclic system linked through an ether group and an ester group, giving the rigid 11H-dibenzo[b,e][1,4]dioxepin-11-one ring (► Fig. 1) [14–16]. The biosynthesis of depsidones occurs via the acetate-malonate pathway, with acetyl-Coenzyme A as the precursor and PKS as the responsible enzyme (► Fig. 2) [17]. Several bioactive depsidones such as stictic acid, salazinic acid, and psomoric acid have been identified [18–20]. The chemical structures of different depsidones of lichens are depicted in ► Fig. 3.


This paper aims to provide up-to-date knowledge and an overview of the biological interest of lichen depsidones. This review includes pharmacological information for those depsidones that have been investigated with potential bioactivity. Original papers published in English in PubMed/Medline and Scholar Google without date restriction were included. Those articles with lichen extracts rich in depsidones were excluded from this review. It is important to emphasize that more depsidones have been identified, such as notatic acid, nortotatic acid, and diploicin, but their pharmacological activities have not been investigated yet.

## Chemistry and Biochemical Origin

The depsidones and the majority of other secondary metabolites in lichens are produced by lichen-forming fungi and are deposited on the outer surface of the hyphal cell walls in the medullary layer of the lichen thallus (► Fig. 4) [21]. The interactions between the mycobiont and photobiont affect the production of secondary metabolites in lichens. For example, several studies have shown that mycobionts within the lichen thallus produce a variety of secondary metabolites in contrast with axenic mycobiont cultures [22–24]. The production of secondary metabolites in the lichen thallus has also been found to be affected by environmental factors (i.e., UV-radiation, climatic conditions, habitats, and presence of non-photosynthetic bacteria and other fungi in lichen thallus) [25–30].

Depsidones consist of 2 or rarely 3 aromatic rings joined by ester linkages and an ether linkage between the rings. The rings are based on the structure of orsellinic acid. Depsidones are grouped in an orcinol or B-orcinol series, depending on the presence of a CH<sub>3</sub> on the C3 carbon of their rings (► Fig. 1) [31–33].

Acetate and malonate units are condensed to form orsellinic acid or B-orsellinic acid that is a precursor for the biosynthesis of several secondary metabolites in lichens and fungi in general (► Fig. 2). Depsidones are produced by the condensation of 2 or





► **Fig. 2** Biosynthesis of depsidones.


more hydroxybenzoic acids through which the carboxyl group of 1 molecule is esterified with a phenolic hydroxyl group of a second molecule. Depsides are precursors for the biosynthesis of depsidones [34]. It is widely accepted that the depsidones are formed from depsides by a loss of hydrogen in an oxidative cyclization process (► **Fig. 2**) [35,36]. Several depside-depsidone pairs are found in lichens, for example, *Pseudevernia furfuracea* contains the depside-depsidone pair (i.e., olivetoric acid and physodic acid) [37]. O-methylation (methylation of oxygen) is a common process and the cause of chemical variation in depsidones in lichens [36]. However, from chemical synthesis producing high yields of several

depsidones, it is proposed that depsidones are biosynthesized in 4 steps: by hydroxylation, acyl group migration, Smiles rearrangement, and esterification [38].



Both the depside and depsidones are products of a nonreducing PKS encoded in the genome of the mycobiont [26,39]. Therefore, the phylogenetic studies of PKS domains, sequencing of complete PKS gene clusters, and the availability of whole-genome sequence data have enabled a more detailed study of the biosynthetic origin of the nonreducing polyketides in lichens [40–44].

 $\alpha$ -alectoronic acid


Ceratinalone




Conhyprotocetraric

 $\alpha$ -Collatolic acid


Connorstictic acid




Constictic acid



Cryptostictic acid




8'-O-ethylstictic




Flavicansone

► Fig. 3 Chemical structure of different depsidones of lichens.


continued




Fumarprotocetraric acid




Gangaleoidin




3-hydroxyphysodic acid




Hypoprotocetraric acid




Hypostictic acid




Lobaric acid




8'-O-methylstictic acid




Norstictic acid




Pannarin



Peristictic acid




Physodalic acid



Physodic acid

► Fig. 3 Continued






## Molecular Mechanism of Action of Lichen Depsidones

Little is known about the molecular mechanisms through which depsidones exhibit their activities. This review presents some examples; however, further studies are needed to elucidate the diverse properties of this group of secondary metabolites in lichens.

One of the most investigated activities in lichens is their antioxidant activity. Depsidones have been demonstrated to act as antioxidants by directly scavenging ROS and RNS and by modulating redox enzyme activity and expression (i.e., superoxide dismutase and catalase) and transcription factors expression (i.e., Nrf2) [45]. Depsidones can incorporate into cellular lipid microdomains that make them more efficient as antioxidants than other lichen secondary metabolites [46].

Depsidones have also shown cytotoxic activity against diverse cancer cell lines (i.e., melanoma, breast, and colon). These bioactive compounds exert cytotoxic effects through diverse signaling pathways. Hence, depsidones can attenuate cell tumor growth by acting as selective inhibitors of Plk1 activity. Plk1 is a serine/threonine kinase that is overexpressed in human tumors, and it is related to invasive potential and lower cancer-related survival [47]. In addition, depsidones also directly target antiapoptotic Bcl-2



► **Fig. 4** Cross-section of lichen thallus showing cortical and medullary hyphae.

family proteins [48]. High expression of antiapoptotic Bcl-2 family proteins (i.e., Bcl-2) contributes to the expansion of malignant cells and reduces the therapeutic efficacy of cytotoxic drugs [49]. Moreover, these secondary metabolites are promising cytotoxic agents via oxidative stress induction; the overproduction of ROS disrupts redox homeostasis and leads to severe structural and functional injury in cancer cells [50]. Furthermore, depsidones inhibit lipoxygenases, which are involved in cell viability and proliferation, and migration, invasion, and metastasis of cancer cells [51]. Besides, depsidones can suppress carcinomas by targeting the HGF-c-Met signaling pathway [52]. c-Met is a receptor tyrosine kinase, and HGF is the ligand for this receptor. Dysregulation of the HGF-c-Met signaling pathway promotes tumor progression and metastasis by stimulating different signaling pathways as JAK/STAT and PI3K/AKT [53]. Finally, other depsidones act as cytotoxic agents by targeting the aberrant Wnt/ $\beta$ -catenin signaling [20].

Depsidones have also antimicrobial properties against Gram-positive bacteria, Gram-negative bacteria, and fungi. Particularly, some depsidones are RecA inhibitors, which potentiate bactericidal activity and reduce antibiotic resistance [54]. Moreover, depsidones have also targeted the  $\beta$ -hydroxyacyl-acyl carrier protein FabZ of the bacterial system for FAS [55]. Furthermore, depsidones have proven to be promising antiviral agents against alpha-viruses via nsP1 GTP binding and guanylation inhibition. These RNA viruses need a 5' cap structure in whose formation viral protein nsP1 participates and which is necessary to avoid viral RNA degradation [56].

Other depsidones are reported for pharmacological inhibition of protein tyrosine phosphatase 1B (involved in insulin resistance) [57]. Moreover, these compounds act in other signal transduction pathways such as epidermal growth factor receptor, integrin signaling pathways, and cell cycle regulation [58]. Furthermore, they have anti-inflammatory properties by inhibiting cytokine expression and NO production through NF- $\kappa$ B/MAPK and inflammasome NLRP3 pathways [59, 60].

## Pharmacological Activity of Lichen Depsidones

Pharmacological activities of lichen depsidones are summarized in

► **Table 1.**

### Alectoronic acid

Alectoronic acid has been shown to have cytotoxic activity against the B16 murine melanoma cell line. It reduced cancer cell viability with a higher potency than the reference compound cisplatin ( $IC_{50}$  of 10.3  $\mu$ M for alectoronic acid and  $IC_{50}$  of 30.3  $\mu$ M for cisplatin) [61].

### Collatolic acid

Collatolic acid showed antimicrobial properties against methicillin-resistant clinical isolates strains of *Staphylococcus aureus* with an  $MIC_{90}$  value of 128  $\mu$ g/mL. Moreover, combinations of collatolic acid and gentamicin led to a synergistic antimicrobial effect, whereas antagonism occurred when collatolic acid and levofloxacin were associated [62]. Additional antimicrobial action against *Escherichia coli* RecA protein has been reported for collatolic acid. This compound exhibited a percentage of RecA inhibition of

103.4%, and it acted as a noncompetitive inhibitor for ATP binding site [63].

### Fumarprotocetraric acid

Fumarprotocetraric acid has been mainly investigated for its antimicrobial properties. Hence, this compound showed antimicrobial action against Gram-positive bacteria (especially *Bacillus cereus* and *Bacillus subtilis* with MIC values of 4.6  $\mu$ g/mL), Gram-negative bacteria (especially, *Listeria monocytogenes* with MIC value of 4.6  $\mu$ g/mL), and fungi (*Candida albicans* and *Candida glabrata* with MIC values of 18.7  $\mu$ g/mL) in the disk diffusion method [64]. In another study, this depsidone was more active against bacteria than fungi, and its action against *Klebsiella pneumoniae* (MIC value of 0.031 mg/mL) was particularly remarkable [65]. However, fumarprotocetraric acid has resulted to be ineffective towards MRSA strains [66]. Apart from its antibacterial activity, fumarprotocetraric acid showed antitrypanosomal activity against *Trypanosoma brucei brucei* [67].

In addition to antimicrobial properties, fumarprotocetraric acid is a promising antioxidant compound. The neuroprotection exerted in neuroblastoma and astrocytoma cell lines by fumarprotocetraric acid has been related to its ability to reduce ROS formation, lipid peroxidation, and GSH depletion [68]. Moreover, fumarprotocetraric acid demonstrated *in vivo* expectorant and antioxidant properties in an albino Swiss mice model at 25 and 50 mg/kg as evidenced in an increase of excretions and a reduction of lipid peroxidation in lung tissue [69].

Finally, fumarprotocetraric acid did not show photoprotective properties (SPF value [1.91] and PF-UVA value [1.75]) [70].

### 3-Hydroxyphysodic acid

This compound induced cytotoxicity against rat thymocytes and diminished their proliferation via antioxidant/oxidant imbalance [71]. In addition, 3-hydroxyphysodic showed antimicrobial activities. It acted as a larvicidal agent against second and third instar larvae of the mosquito *Culiseta longiareolata* ( $LC_{50}$  values 0.97 ppm) as well as antibacterial and antifungal agent with MIC values from 0.08 to 2.57 mM against *B. cereus*, *E. coli*, *L. monocytogenes*, *Salmonella typhimurium*, *S. aureus*, and *C. albicans* [72, 73].

### Lobaric acid

The *in vitro* cytotoxic activity of lobaric acid has been tested in many different cancer cell lines such as human breast adenocarcinoma MCF-7 cells, human colon carcinoma HCT-116 cells, and human malignant glioma U87MG cells [48, 50, 74–77]. Lobaric acid effectively reduced cancer cell viability and proliferation, targeting the anti-apoptotic Bcl-2 protein and the cleaved form of the PARP [48]. This depsidone also exerted cytotoxic action via oxidative stress induction as evidenced in high levels of 8-OH-dG (DNA damage) [50]. Further, lobaric acid reduced cancer cell growth through the inhibition of 5-lipoxygenase and 12-lipoxygenase [74, 75, 77]. Furthermore, this compound inhibited the polymerization of tubulin in a concentration-dependent manner, and this activity is structurally related to hydroxyl groups at C-1' and C-2' and carboxylic acid [78]. Finally, lobaric acid also inhibited mitochondrial thioredoxin reductase in rat lungs [79].

► **Table 1** Pharmacological activity of lichen depsidones.

Depsidone	Botanical origin	Type of study	Experimental model	Activities	Results	References
$\alpha$ -Alectoronic acid	<i>Ochrolechia parella</i> (L.) Massal	<i>In vitro</i>	Mouse melanoma B16 cell line	Cytotoxic	Cytotoxic activity (IC <sub>50</sub> = 10.3 $\mu$ M)	[61]
Ceratinalone	<i>Usnea ceratina</i> Ach.	<i>In vitro</i>	Human epithelial carcinoma HeLa, Human lung cancer NCI-H46, Liver hepatocellular carcinoma HepG2, Human breast cancer MCF-7 cell lines	Cytotoxic	Moderate activity	[133]
$\alpha$ -Collatolic acid	<i>Lecanora atra</i> (Huds.) Ach.	<i>In vitro</i>	<i>Escherichia coli</i> RecA protein	Antimicrobial	High RecA inhibition (103.4%) Uncompetitive inhibitors for ATP binding	[63]
	<i>Lecanora atra</i> (Huds.) Ach.	<i>In vitro</i>	Methicillin-resistant <i>S. aureus</i> strains	Antimicrobial	Antimicrobial activity (MIC <sub>90</sub> = 128 $\mu$ g/mL) Synergism with gentamicin	[62]
Conhyprotocetraric acid	<i>Ramalina</i> genus	<i>In silico</i>	Computational studies	Antioxidant	Hydroxyl and superoxide anion radical scavengers in polar environments	[131]
Connorstic acid	<i>Ramalina</i> genus	<i>In silico</i>	Computational studies	Antioxidant	Hydroxyl and superoxide anion radical scavengers in polar environments	[131]
Cryptostictic acid	<i>Ramalina</i> genus	<i>In silico</i>	Computational studies	Antioxidant	Hydroxyl and superoxide anion radical scavengers in polar environments	[131]
Deoxystrictic acid	<i>Hypotrachyna revoluta</i> (Flörke) Hale.	<i>In vitro</i>	Radical scavenging activity	Antioxidant	↑ scavenger (13.176 Trolox equivalents)	[126]
8'-O-ethylstictic	<i>Usnea ceratina</i> Ach.	<i>In vitro</i>	Human epithelial carcinoma HeLa cell line Human lung cancer NCI-H460 cell line Hepatocellular carcinoma HepG2 cell line Human breast cancer MCF-7 cell line	Cytotoxic	Moderate cytotoxicity against all cancer lines	[133]
Flavicansone	<i>Teloschistes flavicans</i> (Sw.) Norman.	<i>In vitro</i>	Human promyelocytic leukemia HL 60 cell line	Cytotoxic	Moderate activity (IC <sub>50</sub> value of 58.18 $\mu$ M)	[130]
Fumarprotocetraric acid	<i>Cetraria islandica</i> (L.) Ach.	<i>In vitro</i>	<i>T. brucei brucei</i>	Antimicrobial	Antitrypanosomal activity	[67]
	–	<i>In vitro</i>	Methicillin-resistant <i>S. aureus</i> strains	Antimicrobial	No activity	[66]
	<i>Cladonia foliacea</i> (Huds.) Willd.	<i>In vitro</i>	Gram-positive bacteria: <i>B. cereus</i> , <i>B. subtilis</i> , <i>S. aureus</i> , <i>S. faecali</i> Gram-negative bacteria: <i>P. vulgaris</i> , <i>L. monocytogenes</i> , <i>A. hydrophila</i> Fungi: <i>C. albicans</i> , <i>C. glabrata</i>	Antimicrobial	Antimicrobial activity against all microorganisms	[64]

continued



▶ Table 1 Continued						
Depsidone	Botanical origin	Type of study	Experimental model	Activities	Results	References
	<i>Cladonia furcata</i> (Hudson) Schrade	In vitro	Gram-positive bacteria: <i>B. mycooides</i> , <i>B. subtilis</i> , <i>S. aureus</i> Gram-negative bacteria: <i>E. cloacae</i> , <i>E. coli</i> , <i>K. pneumoniae</i> Fungi: <i>A. flavus</i> , <i>A. fumigatus</i> , <i>B. cinerea</i> , <i>C. albicans</i> , <i>F. oxysporum</i> , <i>M. mucedo</i> , <i>P. variotii</i> , <i>P. purpurescens</i> , <i>P. verrucosum</i> , <i>T. harsianum</i>	Antimicrobial	More activity against bacteria than fungi The lowest MIC value (0.031 mg/mL) against <i>K. pneumoniae</i>	[65]
	<i>Cetraria islandica</i> (L.) Ach.	In vitro	Human neuroblastoma SH-SY5Y cell line Human U373 MG astrocytoma cell line Hydrogen peroxide-induced oxidative stress model	Antioxidant	↑ Cell viability ↓ ROS formation, lipid peroxidation, and GSH depletion ↓ Apoptosis, ↓ caspase-3 activity, and expression; ↓ Bax and ↑ Bcl-2 proteins levels ↑ CAT, SOD-1, and HO-1 expression	[68]
	<i>Cladonia verticillaris</i> (Raddi) Fr.	In vivo	Albino Swiss mice	Antioxidant Expectorant	↑ Expectorant activity ↓ Lipid peroxidation	[69]
	<i>Lasallia pustulata</i> (L.) Mérat	In vitro	Sun protection factor (SPF) protection Factor-UVA (PF-UVA)	Photoprotection	SPF value: 1.91 (commercial filters ranged 3.91 to 11.16) PF-UVA value: 1.75. Commercial filter: 2.76	[70]
Gangaleoidin	<i>Ramalina</i> genus	In silico	Computational studies	Antioxidant	Hydroxyl and superoxide anion radical scavengers in polar environments	[131]
3-Hydroxyphysodic acid	<i>Hypogymnia tubulosa</i> (Schaer.) Hav.	In vitro	Second and third instar larvae of the mosquito <i>Culiseta longiareolata</i>	Antimicrobial	Larvicidal activity (LC <sub>50</sub> values 0.97 ppm)	[72]
	<i>Hypogymnia tubulosa</i> (Schaerer) Hav.	In vitro	Gram-positive bacteria: <i>Bacillus cereus</i> , <i>Staphylococcus aureus</i> Gram-negative bacteria: <i>Escherichia coli</i> , <i>Salmonella typhimurium</i> Fungi: <i>Candida albicans</i>	Antimicrobial	MIC values from 0.08 to 2.57 mM	[73]
	<i>Hypogymnia physodes</i> (L.) Nyl.	In vitro	Rat thymocytes	Cytotoxic	↑ cytotoxicity ↓ proliferation No effects on MMP and ROSA	[71]
Hypoprotocetraric	<i>Ramalina</i> genus	In silico	Computational studies	Antioxidant	Hydroxyl and superoxide anion radical scavengers in polar environments	[131]
Hypostictic acid	<i>Pseudoparmelia sphaerospora</i> (Nyl.) Hale.	In vitro	<i>M. tuberculosis</i>	Antimicrobial	Antitubercular activity Moderate inhibitory activity (MIC = 94.0 µg/mL)	[93]

continued

▶ Table 1 Continued

Depsidone	Botanical origin	Type of study	Experimental model	Activities	Results	References
Lobaric acid	<i>Stereocaulon alpinum</i> Laurer	<i>In vitro</i>	Human breast adenocarcinoma MCF-7 Human cervix adenocarcinoma HeLa Human colon carcinoma HCT-116 cell lines	Cytotoxic	↓ HeLa and HCT-116 cell viability	[76]
	<i>Stereocaulon alpinum</i> Laurer	<i>In vitro</i>	Peripheral venous blood	Cytotoxic	Potent 12(S)-LOX inhibitor (93.4%)	[75]
	<i>Usnea longissima</i> Ach.	<i>In vitro</i>	Papillary renal cell carcinoma cell line Human malignant glioma U87MG cell line	Cytotoxic	↑ LDH and 8-oxo-dG levels PRCC cells (IC <sub>50</sub> = 9.08 mg/L) U87MG (IC <sub>50</sub> = 5.77 mg/L)	[50]
	<i>Stereocaulon alpinum</i> Laurer	<i>In vitro</i>	Pancreas cell cancer (Capan-1, Capan-2) Breast cell cancer (T47-D) Prostate cell cancer (PC-3) Lung cell cancer (NCI-H1417) Ovary cell cancer (NIH: OVCA9-3) Stomach cell cancer (AGS) Colorectal cell cancer (WiDr) Blood cell cancer (HL-60, K-562) cell lines	Cytotoxic	5-LOX and 12-LOX inhibitory activity ↑ Inhibitory effect against all cell lines (EC <sub>50</sub> = 15.2–65.5 µg/mL)	[77]
	<i>Stereocaulon paschale</i> (L.) Hoffm.	<i>In vitro</i>	LPS-stimulated macrophages	Anti-inflammatory	↓ NF-κB activation ↓ IL-1β and TNF-α secretion	[59]
	<i>Stereocaulon alpinum</i> Laurer	<i>In vitro</i>	Porcine leucocytes	Anti-inflammatory	Inhibitory effects on 5-LOX (IC 50 7.3 µM)	[84]
	–	<i>In vitro</i>	Human HaCaT keratinocytes cell line	Anti-inflammatory	Block trypsin-induced and SLICKV-NH2-induced PAR2 activation ↓ mobilization of intracellular Ca <sup>2+</sup> ↓ expression of IL-8 PAR2 antagonist	[82]
	<i>Stereocaulon alpinum</i> Laurer	<i>In vitro</i>	TNF-α-Stimulated Vascular Smooth Muscle Cells	Anti-inflammatory	↓ VCAM-1 and TNF-R1 expression	[83]
	<i>Stereocaulon alpinum</i> Laurer	<i>In vitro</i>	LPS-stimulated macrophages	Anti-inflammatory	↓ NO production, COX-2 expression, and PG2 expression ↓ TNF-α, IL-1, β IL-6, and IL-18 production Inhibition of NLRP3 inflammasome activation Downregulating NF-κB/MAPK pathways	[60]
	<i>Stereocaulon alpinum</i> Laurer	<i>In vitro</i>	<i>E. coli</i> RecA protein	Antimicrobial	High RecA inhibition (96.8%)	[63]
	<i>Stereocaulon alpinum</i> Laurer	<i>In vitro</i>	Methicillin-resistant <i>S. aureus</i> strains	Antimicrobial	Antimicrobial activity (MIC <sub>50</sub> = 32 µg/mL MIC <sub>90</sub> = 64 µg/mL) Synergic only for gentamicin	[62]

continued

► **Table 1** Continued

Depsidone	Botanical origin	Type of study	Experimental model	Activities	Results	References
	–	<i>In vitro</i>	Baby hamster kidney BHK17 cell line Monkey Vero E6 cell line Human liver Huh7 cell line Sindbis virus and Chikungunya virus	Antimicrobial	Anti-alphaviral ↓ CHIKV nsP1 GTP-binding and guanylation activities ↓ virus growth	[56]
	<i>Stereocaulon alpinum</i> Laurer	<i>In vitro</i>	<i>M. aurum</i>	Antimicrobial	Antimycobacterial activity (MIC values ≥ 125 µg/mL)	[85]
	–	<i>In silico</i>	Drug-binding studies on the structure of Nsp1 from SARS-CoV-2	Antimicrobial	Lobaric acid bind to Nsp1 Potential inhibitor blocking viral RNA binding	[86]
	<i>Cladonia</i> sp.	<i>In vitro</i>	SOR assay, NO assay, DPPH assay	Antioxidant	SOR (IC <sub>50</sub> = 97.9 µmol) No DPPH activity	[87]
	<i>Stereocaulon alpinum</i> Laurer	<i>In vitro</i>	Human cervix adenocarcinoma HeLa cell line Colon carcinoma HCT116 cell line	Cytotoxic	↓ HeLa and HCT116 cells proliferation ↑ Apoptosis ↓ Bcl-2 ↑ PARP	[48]
	<i>Stereocaulon sasakii</i> Zahlbr.	<i>In vitro</i>	Tubulin protein	Cytotoxic	Inhibition tubulin polymerization (IC <sub>50</sub> = 100 µM)	[78]
	<i>Stereocaulon alpinum</i> Laurer	<i>In vitro</i>	Breast cell cancer (T-47D and ZR-75-1) Erythro-leukemia cell cancer (K-562) Normal skin fibroblasts Peripheral blood lymphocytes	Cytotoxic	↓ DNA synthesis in malignant cells ↑ Cell death in malignant cells 5-LOX inhibitory activity	[74]
	–	<i>In vitro</i>	Mitochondrial TrxR purified from rat lung	Cytotoxic	↑ Inhibitory effect	[79]
	<i>Stereocaulon alpinum</i> Laurer	<i>In vitro</i>	PTP1B inhibition assay	Enzyme inhibition	PTP1B inhibitory activity	[81]
	<i>Stereocaulon alpinum</i> Laurer	<i>In vitro</i>	PTP1B inhibition assay	Enzyme inhibition	Potent PTP1B inhibitory activity (IC <sub>50</sub> = 0.87 µM)	[80]
	<i>Stereocaulon alpinum</i> Laurer	<i>In vivo</i>	<i>T. coli</i> from guinea pigs	Muscle relaxant	↓ Spontaneous muscle contractile activity	[88]
8'-O-methylstictic	<i>Hypotrachyna revoluta</i> (Flörke) Hale.	<i>In vitro</i>	Radical scavenging activity	Antioxidant	(61.85) Trolox® equivalents	[126]
	<i>Hypotrachyna caraccensis</i> (Taylor) Hale	<i>In vitro</i>	DPPH assay	Antioxidant	Low-moderate scavenging activity	[132]
Norstictic acid	<i>Ramalina</i> sp.	<i>In vitro</i>	<i>M. tuberculosis</i>	Antimicrobial	Antitubercular activity (MIC = 62.5 µg/mL)	[93]
	<i>Toninia candida</i> (Weber) Th.Fr.	<i>In vitro</i>	Gram-positive bacteria: <i>B. mycoides</i> , <i>B. subtilis</i> , <i>S. aureus</i> Gram-negative bacteria: <i>E. coli</i> , <i>K. pneumoniae</i> Fungi: <i>A. flavus</i> , <i>A. fumigatus</i> , <i>C. albicans</i> , <i>P. purpurescens</i> , <i>P. verrucosum</i>	Antimicrobial	Moderate antimicrobial activity (MIC value = 0.25 to 1 mg/mL)	[90]
						continued

► Table 1 Continued

Depsidone	Botanical origin	Type of study	Experimental model	Activities	Results	References
	<i>Ramalina farinacea</i> (L.) Ach.	<i>In vitro</i>	Gram-positive bacteria: <i>B. subtilis</i> , <i>L. monocytogenes</i> , <i>P. vulgaris</i> , <i>S. aureus</i> , <i>E. faecalis</i> Gram-negative bacteria: <i>A. hydrophila</i> Fungi: <i>C. albicans</i> , <i>C. glabrata</i>	Antimicrobial	Low antimicrobial activity	[92]
	<i>Rhizoplaca aspidophora</i> (Vain.) Redón	<i>In vitro</i>	<i>E. coli</i> RecA protein	Antimicrobial	Low RecA inhibition (18.2%)	[63]
	<i>Stereocaulon montagneanum</i> I. M. Lamb.	<i>In vitro</i>	DPPH assay SOR assay	Antioxidant	Low DPPH radical scavenging activity High SOR scavenging activity	[91]
	<i>Toninia candida</i> (Weber) Th.Fr.	<i>In vitro</i>	DPPH assay SOR assay	Antioxidant	High antioxidant activity (DPPH IC <sub>50</sub> = 102.65 µg/ml and SOR IC <sub>50</sub> = 133.46 µg/ml)	[90]
	<i>Ramalina</i> sp.	<i>In vitro</i>	Human melanoma UACC-62 cell line Mouse melanoma B16-F10 cell line Mouse 3T3 normal cells	Cytotoxic	↑ Stronger activity against UACC-62 melanoma cells Selective action against malignant cells	[89]
	<i>Usnea strigosa</i> (Ach.)	<i>In vitro</i>	Human breast cancer (MDA-MB-231, MDA-MB-468, MCF-7, T-47D, BT-474, SK-BR-3) cell lines Human mammary epithelial (MCF-10A) cell line Female athymic nude mice	Cytotoxic	↓ MDA-MB-231 cell proliferation, migration, and invasion ↓ Tumor size and tumor weight ↑ Tolerability	[52]
	<i>Stereocaulon montagneanum</i> I. M. Lamb.	<i>In vitro</i>	Murine melanocytes B16 cell line Human keratinocyte HaCaT cell line UV-model	Cytotoxic	No cytotoxic No sunscreen action	[91]
	<i>Toninia candida</i> (Weber) Th.Fr.	<i>In vitro</i>	Human melanoma FemX cell line Human colon carcinoma LS174 cell line	Cytotoxic	High cytotoxic activity ↑ Number of cells in sub-G1 phase	[90]
Pannarin	<i>Psoroma</i> sp.	<i>In vitro</i>	<i>E. coli</i> RecA protein	Antimicrobial	Low RecA inhibition (13.1%)	[63]
	<i>Psoroma</i> spp.	<i>In vitro</i>	Methicillin-resistant <i>S. aureus</i>	Antimicrobial	Bactericidal (MIC <sub>50</sub> = 4 µg/ml; MIC <sub>90</sub> = 8 µg/ml)	[97]
	<i>Psoroma pallidum</i> Nyl.	<i>In vitro</i>	Promastigotes forms of <i>Leishmania</i> spp	Antimicrobial	Total lysis of parasites (50 µg/ml)	[98]
	<i>Psoroma</i> spp.	<i>In vitro</i>	pBR322 plasmid DNA model SOR assay	Antioxidant	↓ NO-induced DNA damage Dose-dependent SOR scavenging effect	[95]
	<i>Psoroma</i> spp.	<i>In vitro</i>	Human PBMC cell line	Cytotoxic	Moderate cytotoxic effect	[97]
	<i>Psoroma</i> spp.	<i>In vitro</i>	Red blood cells	Cytotoxic	Significant hemolytic capacity	[96]
	<i>Psoroma</i> spp.	<i>In vitro</i>	Normal human prostatic epithelial DU-145 cell line	Cytotoxic	↓ Cell growth ↑ LDH release at 50 mM ↑ DNA fragmentation ↑ ROS	[94]

► **Table 1** Continued

Depsidone	Botanical origin	Type of study	Experimental model	Activities	Results	References
Peristictic acid	<i>Psoroma</i> spp.	<i>In vitro</i>	Human melanoma M14 cell line	Cytotoxic	↓ Cell growth ↑ LDH release at 50 mM ↑ DNA fragmentation ↑ ROS	[95]
	<i>Psoroma</i> spp.	<i>In vitro</i>	8-MOP-human serum albumin photobinding	Photoprotection	Inhibition of photobinding (35.2%)	[99]
Physodic acid	<i>Stereocaulon montagneum</i> I. M. Lamb.	<i>In vitro</i>	DPPH assay SOR assay	Antioxidant	DPPH scavenging activity (10%) High SOR scavenging activity	[91]
	<i>Stereocaulon montagneum</i> I. M. Lamb.	<i>In vitro</i>	Murine melanocytes B16 cell line Human keratinocyte HaCaT cell line UV-model	Cytotoxic	No cytotoxic No sunscreens action	[91]
Physodic acid	<i>Pseudevernia furfuracea</i> (L.) Zopf	<i>In silico</i> <i>In vitro</i>	Virtual screening using validated pharmacophore models Microsomal fraction IL-1 $\beta$ -stimulated A549 cells	Anti-inflammatory	Potential inhibitors of microsomal prostaglandin E2 synthase 1 Inhibitors of mPGES-1 (IC50 = 0.4 $\mu$ M)	[107]
	<i>Hypogymnia physodes</i> (L.) Nyl.	<i>In vitro</i>	Gram-positive bacteria: <i>B. mycoides</i> , <i>B. subtilis</i> ; Gram-negative bacteria: <i>E. coli</i> , <i>K. pneumoniae</i> Fungi: <i>A. flavus</i> , <i>A. fumigatus</i> , <i>C. albicans</i> , <i>P. purpurescens</i> , <i>P. verrucosum</i>	Antimicrobial	Antimicrobial activity (especially against <i>B. subtilis</i> and <i>B. mycoides</i> with MIC values of 0.0008 and 0.0016 mg/mL, respectively)	[101]
Physodic acid	<i>Pseudevernia furfuracea</i> (L.) Zopf	<i>In vitro</i>	Cultured human amnion fibroblasts	Antioxidant	< 50 mg/L no oxidative stress and genotoxicity	[108]
	<i>Pseudevernia furfuracea</i> (L.) Zopf	<i>In vitro</i>	Cultured Human lymphocytes (HLs)	Antioxidant	↑ Total antioxidant capacity (0.5–10 mg/L)	[109]
Physodic acid	<i>Hypogymnia physodes</i> (L.) Nyl.	<i>In vitro</i>	DPPH assay SOR assay Reducing power	Antioxidant	High DPPH radical scavenging activity (IC50 69.11 $\mu$ g/mL) High SOR scavenging activity (IC50 = 118.17 $\mu$ g/mL) High reducing power	[101]
	<i>Hypogymnia lugubris</i> (Pers.) Krog	<i>In vitro</i>	A375 melanoma cancer cell line	Cytotoxic	Apoptosis ↓ Hsp70 expression	[100]
Physodic acid	<i>Pseudevernia furfuracea</i> (L.) Zopf	<i>In vitro</i>	Human U87MG-GBM cell lines Primary rat cerebral cortex (PRCC) cells	Cytotoxic	↓ Cell viability (IC50 values of 698.19 mg/l for PRCC cells and 410.72 mg/L for U87MG cells) ↑ 8-OH-dG levels	[103]
	<i>Hypogymnia physodes</i> (L.) Nyl.	<i>In vitro</i>	Human melanoma FemX cell line Human colon carcinoma LS174 cell line	Cytotoxic	Cytotoxic activity (IC50 = 19.52 $\mu$ g/mL for FemX, IC50 = 17.89 $\mu$ g/mL for LS174) ↑ Number cells in sub-G1 phase ↓ Number cells in S phase and G2/M phase	[101]
Physodic acid	<i>Hypogymnia enteromorpha</i> (Ach.) Nyl.	<i>In vitro</i>	<i>S. typhimurium</i> TA 98	Cytotoxic	Inhibition of reactive metabolites formation	[111]

continued



▶ Table 1 Continued

Depsidone	Botanical origin	Type of study	Experimental model	Activities	Results	References
Physodic acid	<i>Hypogymnia physodes</i> (L.) Nyl.	<i>In vitro</i>	Colorectal cancer cell lines (HCT116 and DLD-1) Human keratinocytes HaCaT cell line	Cytotoxic	↓ Axin2 expression (especially in HCT116 cells) ↓ Survivin and MMP7 expression	[20]
	<i>Hypogymnia physodes</i> (L.) Nyl.	<i>In vitro</i>	Isolated rat thymocytes	Cytotoxic	↓ Thymocytes proliferation ↑ Cytotoxicity ↑ ROS production ↓ MMP	[71]
Physodalic acid	<i>Hypogymnia physodes</i> (L.) Nyl.	<i>In vitro</i>	Human cancer HeLa cell lines	Cytotoxic	↓ Cell viability: IC <sub>50</sub> (24 h incubation) of 171 µg/mL and IC <sub>50</sub> (72 h incubation) of 63 µg/mL	[105]
	<i>Hypogymnia physodes</i> (L.) Nyl.	<i>In vitro</i>	Peripheral human lymphocytes	Cytotoxic	↓ Frequency of MN (28.2%)	[104]
Protocetraric acid	<i>Hypogymnia physodes</i> (L.) Nyl.	<i>In vitro</i>	Breast cancer cell lines (MDA-MB-231, MCF-7, and T-47D) Nontumorigenic MCF-10A cell line	Cytotoxic	Cytotoxic activity (IC <sub>50</sub> 46.0–93.9 µM)	[102]
	–	<i>In vitro</i>	Human colon cancer HCT116 cell line Human leukemic K562 cell line Bladder cancer J82 and UM-UC-3 cell lines Human primary pancreatic adenocarcinoma BxPC-3 cell line	Cytotoxic	Inhibition of M-Phase Phosphoprotein 1 (MPP1) ATPase activity Weak cancer cell inhibitor (EC <sub>50</sub> values ≈ 30 µM)	[106]
Physodalic acid	<i>Pseudevernia furfuracea</i> (L.) Zopf	<i>In vitro</i> <i>Ex vivo</i>	Murine neuroblastoma Neuro2A cells Murine hippocampal primary cultures	Neuroprotection	No cytotoxic effects Neurotrophic and neurogenic activity Modulation gene expression of BDNF and NGF	[110]
	<i>Hypogymnia enteromorpha</i> (Ach.) Nyl.	<i>In vitro</i>	<i>S. typhimurium</i> TA 98	Cytotoxic	Inhibition mutagenicity of a heterocyclic amine, Trp-P-2	[111]
Protocetraric acid	<i>Hypogymnia physodes</i> (L.) Nyl.	<i>In vitro</i>	Isolated rat thymocytes	Cytotoxic	↓ Thymocytes proliferation ↑ Cytotoxicity ↑ ROS production ↓ MMP	[71]
	<i>Hypogymnia enteromorpha</i> (Ach.) Nyl.	<i>In vitro</i>	<i>S. typhimurium</i> strain TA 100	Cytotoxic	↑ Mutagenicity	[111]
Protocetraric acid	<i>Hypogymnia physodes</i> (L.) Nyl.	<i>In vitro</i>	Human cancer HeLa cell lines	Cytotoxic	↓ Cell viability: IC <sub>50</sub> (24 h incubation) of 964 µg/mL and IC <sub>50</sub> (72 h incubation) of 283 µg/mL	[105]
	<i>Hypogymnia physodes</i> (L.) Nyl.	<i>In vitro</i>	Peripheral human lymphocytes	Cytotoxic	↓ Frequency of MN (30.3%)	[104]
Protocetraric acid	<i>Hypogymnia lugubris</i> (Pers.) Krog	<i>In vitro</i>	<i>E. coli</i> RecA protein	Antimicrobial	Low RecA inhibition (11.5%)	[63]
	<i>Flavoparmelia caperata</i> L.	<i>In vitro</i>	<i>S. aureus</i>	Antimicrobial	Antibacterial activity (MIC 12.5 µg/mL)	[113]

continued

► Table 1 Continued						
Depsidone	Botanical origin	Type of study	Experimental model	Activities	Results	References
	<i>Usnea allopunctata</i> Nyl.	In vitro	Gram-positive bacteria: <i>B. subtilis</i> , <i>S. faecalis</i> , <i>S. aureus</i> , <i>S. epidermidis</i> , <i>M. smegmatis</i> Gram-negative bacteria: <i>E. coli</i> , <i>P. mirabilis</i> , <i>P. vulgaris</i> , <i>V. cholerae</i> , <i>K. pneumoniae</i> , <i>P. aeruginosa</i> , <i>S. typhi</i> Fungi: <i>A. flavus</i> , <i>C. albicans</i> , <i>C. tropicalis</i> , <i>C. glabrata</i> , <i>C. gastrii</i> , <i>T. rubrum</i>	Antimicrobial	High activity against <i>S. typhi</i> (MIC value = 0.5 mg/mL), <i>K. pneumoniae</i> (MIC value = 1 mg/mL) and <i>T. rubrum</i> (MIC value = 1 mg/mL)	[112]
	<i>Cetraria islandica</i> (L.) Ach.	In vitro	<i>T. brucei brucei</i>	Antimicrobial	Antitrypanosomal activity	[67]
	<i>Parmelia caperata</i> (Ehrh. ex Ach.) Ach	In vitro	Gram-positive bacteria: <i>B. mycoides</i> , <i>B. subtilis</i> , <i>S. aureus</i> Gram-negative bacteria: <i>E. coli</i> , <i>K. pneumoniae</i> Fungi: <i>A. flavus</i> , <i>A. fumigatus</i> , <i>C. albicans</i> , <i>P. purpurescens</i> , <i>P. verrucosum</i>	Antimicrobial	↑ Antibacterial activity than antifungal activity. High activity against <i>B. mycoides</i> , <i>B. subtilis</i> , and <i>S. aureus</i> (MIC value = 0.015 mg/mL)	[19]
	<i>Parmotrema dilatatum</i> (Vain.) Hale.	In vitro	<i>M. tuberculosis</i>	Antimicrobial	Antitubercular activity (MIC value = 125 µg/mL)	[93]
	<i>Ramalina farinacea</i> (L.) Ach.	In vitro	Gram-positive bacteria: <i>B. subtilis</i> , <i>L. monocytogenes</i> , <i>S. aureus</i> , <i>S. faecalis</i> Gram-negative bacteria: <i>A. hydrophila</i> , <i>P. vulgaris</i> Fungi: <i>C. albicans</i> , <i>C. glabrata</i>	Antimicrobial	Active against <i>C. albicans</i> and <i>C. glabrata</i>	[92]
	<i>Parmelia caperata</i> (Ehrh. ex Ach.) Ach	In vitro	DPPH assay SOR assay	Antioxidant	Strong antioxidant activity (IC <sub>50</sub> = 119.10 µg/mL for DPPH and 177.60 µg/mL for SOR)	[19]
	<i>Parmotrema dilatatum</i> (Vain.) Hale.	In vitro	Human melanoma UACC-62 cell line Mouse melanoma B16-F10 cell line Mouse 3T3 normal cells	Cytotoxic	↑ Stronger activity against UACC-62 melanoma cells Selective action against malignant cells	[89]
	<i>Parmelia caperata</i> (Ehrh. ex Ach.) Ach	In vitro	Human melanoma FemX cell line Human colon carcinoma LS174 cell line	Cytotoxic	Cytotoxic activity (IC <sub>50</sub> = 58.68 µg/mL for FemX, IC <sub>50</sub> = 60.18 µg/mL for LS174) ↑ Number cells in sub-G1 phase ↓ Number cells in S phase	[19]
Psoromic acid	–	In vitro	Monkey kidney epithelial Vero cell line HSV-1 and HSV-2 models of infection	Antimicrobial	Antitherpetic activity HSV-1 replication inhibition (IC <sub>50</sub> = 1.9 µM) HSV-2 replication inhibition (IC <sub>50</sub> = 2.7 µM) HSV-1 DNA polymerase inactivation (IC <sub>50</sub> = 0.7 µM)	[116]
	<i>Squamarina cartilaginea</i> (With.) P. James	In vitro	<i>S. gordonii</i> , <i>P. gingivalis</i>	Antimicrobial	Antibacterial activity against <i>S. gordonii</i> (MIC value = 11.72 µg/mL) and <i>P. gingivalis</i> (MIC value = 5.86 µg/mL)	[117]
						continued

► Table 1 Continued

Depsidone	Botanical origin	Type of study	Experimental model	Activities	Results	References
	-	<i>In vitro</i>	<i>M. tuberculosis</i> strains	Antimicrobial	Antituberculosis activity (MIC values = 3.2–4.1 µM) Remarkable inhibition UGM (85.8%) and TBNAT (77.4%)	[118]
	-	<i>In vitro</i>	<i>S. aureus</i> <i>E. coli</i> <i>M. tuberculosis</i> <i>P. berghei</i> liver stage (LS) parasites <i>P. falciparum</i> blood-stage (BS) parasites	Antimicrobial	Antibacterial/Antimycobacterial Activity ↓ Growth bacterial  Antiplasmodial activity Moderate LS activity (IC <sub>50</sub> = 31.6 µM), high BS potential (IC <sub>50</sub> = 29.2 µM) Plasmodial FAS-II enzyme (PffabI, PffabG, and PffabZ) inhibition	[119]
	<i>Usnea complanata</i> (Müll. Arg.) Motyka.	<i>In vivo</i>	FRSA assay NORSA assay LPI assay HMGR inhibitory activity ACE inhibitory activity	Antioxidant	Moderate-to-strong antioxidant activity (IC <sub>50</sub> values 0.174–0.271 mg/mL) Competitive type of HMGR inhibition and mixed type of ACE inhibition	[120]
	-	<i>In vitro</i>	Fluorometric Assay	Cytotoxic	↑ RabGTPase inhibition (IC <sub>50</sub> = 1.3 µM)	[114]
	-	<i>In vitro</i>	Splicing assay	Cytotoxic	Pre-mRNA splicing inhibitor	[115]
	-	<i>In vitro</i>	Primary cultures of rat hepatocytes	Cytotoxic	↑ Caspase 3 activity ↑ Subdiploid nuclei %	[18]
	<i>Usnea</i> sp	<i>In vitro</i>	Human melanoma UACC-62 cell line Mouse melanoma B16-F10 cell line Mouse 3T3 normal cells	Cytotoxic	↑ Stronger activity against UACC-62 melanoma cells Selective action against malignant cells	[89]
	-	<i>In vivo</i>	Zebrafish embryos ( <i>B. rerio</i> ) model	Toxicity	Hepatotoxicity (≥ 40%)	[119]
Salazinic acid	<i>Parmelia saxatilis</i> (L.) Ach	<i>In vitro</i>	<i>E. coli</i> RecA protein	Antimicrobial	Low RecA inhibition (8.4%)	[63]
	<i>Parmelia sulcata</i> Taylor	<i>In vitro</i>	Gram-positive bacteria: <i>B. cereus</i> , <i>B. subtilis</i> , <i>L. monocytogenes</i> , <i>S. aureus</i> , <i>S. faecalis</i> Gram-negative bacteria: <i>A. hydrophila</i> , <i>P. vulgaris</i> , <i>Y. enterocolitica</i> , <i>P. aeruginosa</i> , <i>S. typhimurium</i> Fungi: <i>C. albicans</i> , <i>C. glabrata</i> , <i>A. niger</i> , <i>A. fumigatus</i> , <i>P. notatum</i>	Antimicrobial	Antimicrobial activity specially against <i>B. cereus</i> (MIC values = 63 µg/mL)	[121]
	<i>Parmelia reticulata</i> Taylor.	<i>In vitro</i>	Fungi: <i>S. roffisii</i> , <i>R. solani</i> , <i>R. bataticola</i> , <i>F. udum</i> , <i>P. aphanidermatum</i> , <i>P. debaryanum</i>	Antimicrobial	Moderate active against <i>F. udum</i> (IC <sub>50</sub> = 88.20 µg/mL)	[122]

continued

► Table 1 Continued						
Depsidone	Botanical origin	Type of study	Experimental model	Activities	Results	References
	<i>Parmelia saxatilis</i> (L.) Ach.	In vitro	Gram-positive bacteria: <i>B. mycoides</i> , <i>B. subtilis</i> , <i>S. aureus</i> Gram-negative bacteria: <i>E. coli</i> , <i>K. pneumoniae</i> Fungi: <i>A. flavus</i> , <i>A. fumigatus</i> , <i>C. albicans</i> , <i>P. purpurescens</i> , <i>P. verrucosum</i>	Antimicrobial	↑ Antibacterial activity than antifungal activity	[19]
	<i>Parmelia sulcata</i> Taylor					
	<i>Xanthoparmelia camtschadalis</i> (Ach.) Hale.	In vitro	ORAC assay Human U373 MG astrocytoma cell line Hydrogen peroxide-induced oxidative stress model	Antioxidant	ORAC value (2.74 µmol Trolox equivalents per milligram) ↑ Cell viability ↓ ROS production	[124]
	<i>Everniastrum cirrhatum</i> (Fr.) Hale ex Sipman <i>Rimelia cetrata</i> (Ach.) Hale & Fletcher	In vitro	DPPH assay Anti-linoleic acid peroxidation assay Trolox-equivalent antioxidant capacity assay	Antioxidant	Antioxidant activity (46.4 to 57.2%)	[123]
	–	In vitro	DPPH assay NBT assay Human keratinocytes HaCaT cell line	Antioxidant	Superoxide anion scavenger Good PF-UVA candidate (PF-UVA > 2)	[70]
	<i>Parmelia saxatilis</i> (L.) Ach.	In vitro	DPPH assay SOR assay	Antioxidant	Strong antioxidant activity (IC <sub>50</sub> = 91.57 for DPPH and 138.23 µg/mL for SOR)	[19]
	<i>Parmelia sulcata</i> Taylor					
	–	In vitro	Primary cultures of rat hepatocytes	Cytotoxic	↑ Caspase 3 activity ↑ Subdiploid nuclei %	[18]
	<i>Parmelia saxatilis</i> (L.) Ach.	In vitro	Human melanoma FemX cell line Human colon carcinoma LS174 cell line	Cytotoxic	Cytotoxic activity (IC <sub>50</sub> = 39.02 µg/mL for FemX and IC <sub>50</sub> = 5.67 µg/mL for LS174) ↑ Number cells in sub-G1 phase ↓ Number cells in S phase	[19]
	<i>Parmelia sulcata</i> Taylor					
	<i>Parmelia sulcata</i> Taylor	In vitro	Colorectal cancer HCT116 and DLD-1 cell lines.	Cytotoxic	Moderate cytotoxic effects (100 µM)	[20]
	<i>Everniastrum cirrhatum</i> (Fr.) Hale ex Sipman	In vitro	<i>L. casei</i>	Probiotic	Moderate growth stimulating activity	[123]
	<i>Rimelia cetrata</i> (Ach.) Hale & Fletcher					
	<i>Xanthoparmelia somloensis</i> (Gyeln.) Hale	In vitro	Malignant mesothelioma MM98 cell line Vulvar carcinoma A431 cell line Human keratinocyte HaCaT cell line	Wound healing	Intermediate wound closure	[125]
						continued

► Table 1 Continued

Depsidone	Botanical origin	Type of study	Experimental model	Activities	Results	References
Stictic acid	<i>Rhizoplaca aspidophora</i> (Vain) Redon	In vitro	<i>E. coli</i> RecA protein	Antimicrobial	Low RecA inhibition (16.7%)	[63]
	–	In vitro	<i>F. tularensis</i> , <i>Y. pestis</i>	Antimicrobial	Inhibition of FabZ ( <i>F. tularensis</i> , IC <sub>50</sub> = 13.0 μM and <i>Y. pestis</i> , IC <sub>50</sub> = 27.8 μM)	[55]
	<i>Xanthoparmelia camtschadalis</i> (Ach.) Hale.	In vitro	ORAC assay Human U373 MG astrocytoma cell line Hydrogen peroxide-induced oxidative stress model	Antioxidant	ORAC value (2.32 μmol Trolox equivalents per milligram) ↑ Cell viability ↓ ROS production	[124]
	<i>Stereocaulon montagnanum</i> I. M. Lamb.	In vitro	DPPH assay SOR assay Murine melanocytes B16 cell line Human HaCaT keratinocyte cell lines	Antioxidant	Low DPPH radical scavenging activity ↑ SOR scavenging activity	[91]
	<i>Hypotrachyna revoluta</i> (Flörke) Hale.	In vitro	Hydroxyl radical scavenging assay	Antioxidant	Noteworthy antioxidant activity	[126]
Variolaric acid	–	In vitro	Primary cultures of rat hepatocytes	Cytotoxic	↑ Caspase 3 activity ↑ Subdiploid nuclei %	[18]
	–	In silico	Docking studies	Cytotoxic	p53 activator ↓ Toxic adverse effects	[128]
	–	In vitro In silico	Human Saos-2 cells expressing cancer mutant R175H Docking studies	Cytotoxic	p53 activity restoration Cell cycle inhibitor p21 inducer	[127]
	<i>Ochrolechia deceptionis</i> (Hue) Darb	In vitro	<i>E. coli</i> RecA protein	Antimicrobial	Low RecA inhibition (3.2%)	[63]
	<i>Ochrolechia deceptionis</i> (Hue) Darb.	In vitro	Human breast adenocarcinoma MCF-7 cell line Human cervix adenocarcinoma HeLa cell line Human colon carcinoma HCT-116 cell line	Cytotoxic	No effect	[76]
Vicianin	<i>Psoroma pallidum</i> Nyl., <i>P. pulchrum</i> Malme	In vitro	<i>E. coli</i> RecA protein	Antimicrobial	Moderate RecA inhibition (73.7% inhibition)	[63]
	<i>Psoroma pallidum</i> Nyl. <i>P. pulchrum</i> Malme	In vitro	Human breast adenocarcinoma MCF-7 cell line Human cervix adenocarcinoma HeLa cell line Human colon carcinoma HCT-116 cell line	Cytotoxic	↓ Cell viability (HeLa, IC <sub>50</sub> = 67 μM and HCT-116, IC <sub>50</sub> = 40.5 μM)	[76]
	<i>Psoroma dimorphum</i> Malme	In vitro	Androgen-sensitive LNCaP and androgen-insensitive DU-145 human prostate cancer cells	Cytotoxic	↓ Cell viability ↑ Apoptosis	[129]
	<i>Teloschistes flavicans</i> (Sw.) Norman.	In vitro	HL-60 cells	Cytotoxic	Higher cytotoxicity against HL-60 cells	[130]



Lobaric acid showed high inhibition of PTP1B with an  $IC_{50}$  value of  $0.87 \mu\text{M}$  [80, 81]. Tyrosine phosphatase protein is overexpressed in insulin-resistant states [80]. Indeed, Klamann et al. showed that PTP-1B regulates energy balance, insulin sensitivity, and body fat stores in *in vivo* studies [58].

Lobaric acid could inhibit inflammation in LPS-activated macrophages through regulation of NF- $\kappa$ B/MAPK pathways, NLRP3 inflammasome activation, proinflammatory cytokines suppression (TNF- $\alpha$ , IL-1, IL-6, and IL-18), and NO production inhibition [59, 60]. Moreover, lobaric acid reduced IL-8 expression and targeted PAR2 in an *in vitro* SLIGKV-NH<sub>2</sub>-induced atopic dermatitis model in HaCaT keratinocytes [82]. Additionally, lobaric acid exerted anti-inflammatory activity by inhibiting NF- $\kappa$ B and MAPK signaling pathways in TNF- $\alpha$ -stimulated mouse vascular smooth muscle cells [83]. Furthermore, lobaric acid turned out to be a potent arachidonate-5-lipoxygenase inhibitor ( $IC_{50}$  value of  $7.3 \mu\text{M}$ ) [84].

Lobaric acid also showed antimicrobial activity against bacteria and viruses. Thus, this depsidone inhibited RecA from *E. coli* by noncompetitively binding the ATP site [63]. While it showed moderate activity against *Mycobacterium aurum* [85], the activity against methicillin-resistant clinical isolates strains of *S. aureus* with an  $MIC_{90}$  value of  $64 \mu\text{g/mL}$  was good [62]. Moreover, lobaric acid showed anti-alphaviral activity against *Chikungunya* virus via Nsp1 GTP binding and guanylation inhibition in hamster BHK21 and human Huh 7 cell lines [56]. Furthermore, binding studies of Nsp1 from SARS-CoV-2, a nonstructural protein 1 related to viral processes as viral replication and translation regulation, showed greater binding affinities with lobaric acid [86].

Other assayed activities were its antioxidant activity (superoxide radical scavenging action with  $IC_{50}$  value of  $97.9 \mu\text{mol}$ ) [87] and muscle relaxant as evidenced in the reduction of spontaneous muscle contractile activity in guinea-pig taenia coli [88].

### Norstictic acid

The cytotoxic and antitumor role of norstictic acid has been evaluated in diverse *in vitro* (using different cancer cell lines) and *in vivo* models. Therefore, this compound has been shown to be effective for breast cancer treatment and prevention by targeting the c-Met signaling pathway and by suppressing the MDA-MB-231/GFP tumor growth in mammary cancer cells and breast cancer xenograft models in athymic nude mice [52]. Moreover, norstictic acid exerted a noticeable cytotoxic effect against different human melanoma cell lines (FemX, UACC-62, and B16-F10) [89, 90] by increasing apoptotic cells in the sub-G1 phase [89]. Contrary, other studies reported that norstictic acid was not cytotoxic for melanocyte cells [91].

Concerning its antimicrobial activity, norstictic acid showed low to moderate antibacterial and antifungal action against a wide range of Gram-positive bacteria, Gram-negative bacteria, and fungi [63, 90, 92, 93]. For instance, norstictic acid inhibited *Mycobacterium tuberculosis* growth with a MIC value of  $62.5 \mu\text{g/mL}$  [93] and *E. coli* with a value of  $18.2 \mu\text{g/mL}$  [63].

Norstictic acid has also been shown to be a promising antioxidant agent against superoxide anion. On the other hand, its DPPH radical scavenging activity is not entirely clear, since its activity is contradictory in published works [90, 91].

### Pannarin

Pannarin was able to inhibit the growth of the human melanoma M14 cell line and the human prostatic epithelial DU-145 cell line. Its cytotoxic activity has been related to oxidative stress induction as evidenced in ROS overproduction and DNA fragmentation [94, 95]. Moreover, pannarin showed cytotoxic activity against blood cells through a mechanism of hemolysis [96, 97].

Regarding antimicrobial activity, pannarin acted as bactericidal against methicillin-resistant *S. aureus*, and it also had a low capacity to inhibit *E. coli* RecA protein [63, 97]. Moreover, pannarin was effective as an antiparasitic agent against promastigote forms of *Leishmania* spp [98].

Pannarin also showed antioxidant properties as evidenced in its superoxide radical scavenging capacity and NO-induced DNA damage [95], and it has photoprotector capacity (35.2%) [99].

### Physodic acid

There are several studies on the cytotoxic activity of physodic acid against different cancer and nontumorigenic cell lines from diverse origins (human or animal). Against A375 melanoma cancer cell line, physodic acid exhibited good cytotoxicity via apoptosis with a concentration-response relationship (range  $6.25\text{--}50 \mu\text{M}$ ), showing inhibition of Hsp70 expression [100]. Other studies on FemX and LS174 cell lines revealed significant cytotoxic activity ( $IC_{50}$  value of  $19.52 \mu\text{g/mL}$  for FemX,  $IC_{50}$  value of  $17.89 \mu\text{g/mL}$  for LS174) with moderate proapoptotic activity. The number of cells in the sub-G1 phase increased, and the number of cells in the S phase and G2/M phase was lower, indicating a G0/G1 cell cycle arrest [101]. Moreover, physodic acid was cytotoxic on different breast cancer cell lines (MDA-MB-231, MCF-7, and T-47D) with  $IC_{50}$  values that ranged from  $46.0$  to  $93.9 \mu\text{M}$  [102]. Physodic acid displayed weak cytotoxic activity on human U87MG-GBM cell lines and primary rat cerebral cortex (PRCC) cells ( $IC_{50}$  value of  $698.19 \text{ mg/mL}$  for PRCC cells and  $IC_{50}$  value of  $410.72 \text{ mg/mL}$  for U87MG cells) [103]. Moreover, physodic acid reduced thymocyte proliferation-induced cytotoxicity via oxidative stress mainly through ROS production [71]. On lymphocytes, this depsidone significantly decreased micronucleus frequency (28.2%) compared to the positive control [104]. Furthermore, this compound proved to significantly reduce human cancer HeLa cell viability ( $IC_{50}$  [24 h] value of  $171 \mu\text{g/mL}$  and  $IC_{50}$  [72 h] value of  $63 \mu\text{g/mL}$ ) [105]. In another study, Talapatra et al. concluded that physodic acid was a weak cancer cell inhibitor ( $EC_{50}$  values  $\approx 30 \mu\text{M}$ ) on multiple cancer cell lines (human colon cancer HTC116 cell line, human leukemic K562 cell line, bladder cancer J82 and UM-UC-3 cell lines, and human primary pancreatic adenocarcinoma BxPC-3 cell line) [106]. Physodic acid was studied as a modulator of  $\beta$ -catenin-dependent transcription on colorectal cancer (HCT116 and DLD-1).  $\beta$ -catenin transcription is related to cell survival and proliferation. Physodic acid reduced Axin2 ( $\beta$ -catenin target gene) expression (especially in HCT116 cells) and decreased survivin and MMP7 expression [20]. Also, this depsidone was probed as an inhibitor of MPP1, essential for the cytokinesis process, indicating noncompetitive ATP binding in *in silico* studies [106].

Antimicrobial activity was also examined in bacteria and fungi. Physodic acid had strong inhibitory capacity especially against

*B. subtilis* and *B. mycoides* with MIC values of 0.0008 and 0.0016 mg/mL, respectively [101].

In addition to cytotoxic and antimicrobial properties, *in vitro* and *in silico* models showed the anti-inflammatory activity of physodic acid. Virtual screening evaluation revealed that this depsidone inhibits microsomal prostaglandin E2 synthase-1 [107]. Determination of mPGES-1 inhibition was performed using a microsomal fraction of IL-1 $\beta$ -stimulated A549 cells (IC<sub>50</sub> = 0.43  $\mu$ M) [107].

Physodic acid was also investigated as an antioxidant agent, showing high DPPH radical scavenging activity (IC<sub>50</sub> value of 69.11  $\mu$ g/mL), high SOR scavenging activity (IC<sub>50</sub> value of 118.17  $\mu$ g/mL), and high reducing power [101]. Lower concentrations of physodic acid tested in cultured human amnion fibroblasts (<50 mg/L) and cultured human lymphocytes (0.5–10 mg/L) showed antioxidant capacities [108, 109].

Moreover, physodic acid showed neuroprotective properties, exhibiting neurotrophic and neurogenic activity via modulation of gene expression of BDNF and NGF in *ex vivo* (murine hippocampal primary cultures) and *in vivo* (murine neuroblastoma Neuro2A cells) assays [110].

### Physodalic acid

Cytotoxic activity of physodalic acid is also described. However, compared to physodic acid, physodalic presented weaker activity. Physodalic acid demonstrated a weak reduction of viability (IC<sub>50</sub> [24 h] value of 964  $\mu$ g/mL and IC<sub>50</sub> [72 h] value of 283  $\mu$ g/mL) on human cancer HeLa cell lines [105].

This compound also diminished the proliferation of thymocytes inducing cytotoxicity via ROS production. Physodalic acid reduced the frequency of micronucleus (30.3%) on lymphocytes [71, 104].

Despite being reported as mutagenic in *S. typhimurium* TA 100 [83], physodalic acid inhibited the mutagenicity of a heterocyclic amine, Trp-P-2, in *S. typhimurium* TA 98 [111].

### Protocetraric acid

Most of the studies on protocetraric acid referred to its antimicrobial activity. Particularly, this depsidone inhibited pathogenic bacteria growth such as *S. aureus* (MIC value of 12.5  $\mu$ g/mL), *M. tuberculosis* (MIC value of 125  $\mu$ g/mL), *S. typhi* (MIC value of 0.5 mg/mL), *K. pneumoniae* (MIC value of 1 mg/mL), and *B. mycoides*, *B. subtilis*, and *S. aureus* (MIC value of 0.015 mg/mL) [19, 93, 112, 113]. Moreover, protocetraric acid revealed a marked antifungal activity against *T. rubrum* (MIC value of 1 mg/mL), *C. albicans*, and *C. glabrata* (MIC value of 3.9  $\mu$ g/ $\mu$ l) [92, 112]. Furthermore, protocetraric acid showed trypanocidal activity against *T. brucei brucei* with a MIC value of 6.30  $\mu$ M [67].

Protocetraric acid also demonstrated cytotoxic activity against melanomas cell lines (IC<sub>50</sub> values of 0.52  $\mu$ g/mL for UACC-62 cells and 58.68  $\mu$ g/mL for FemX cells) and colon carcinoma cell line (IC<sub>50</sub> value of 60.18  $\mu$ g/mL for LS174 cells) [19, 89].

This depsidone had also an effective antioxidant action as evidenced in DPPH and superoxide anions radical scavenging activity [19].

### Psoromic acid

Psoromic acid presented an inhibitory effect against melanoma cell lines (UACC-62 and B16-F10) and primary cultures of rat hepatocytes [18, 89]. The cytotoxic activity of psoromic acid was related to its capacity to induce an apoptotic response and to inhibit splicing and Rab GTPase [18, 114, 115].

Psoromic acid was also of interest as an antiviral agent, as it blocked HSV-1 and HSV-2 replication and DNA synthesis [116]. Moreover, this depsidone reduced bacterial growth of *Streptococcus gordonii* (MIC value of 11.72  $\mu$ g/mL), *Porphyromonas gingivalis* (MIC value of 5.86  $\mu$ g/mL), and *M. tuberculosis* strains (3.2–4.1  $\mu$ M) [116–118]. Furthermore, psoromic acid acts as an inhibitor of *Plasmodium* liver stages targeting the plasmodial FAS-II pathway [119]. *In vivo* studies determined that psoromic acid was hepatotoxic in fabp10a: DsRed2 zebrafish larvae ( $\geq$  40%) [119].

Using different *in vitro* antioxidant assays, Behera et al. revealed that psoromic acid had moderate to strong antioxidant activity [120].

### Salazinic acid

Salazinic acid displayed cytotoxic activity against colorectal cancer cell lines (HCT116, DLD-1, and LS174), melanoma cancer cell lines (FemX), and primary cultures of rat hepatocytes by inducing apoptosis and cell cycle arrest [18–20].

Considering its antimicrobial activity, salazinic acid inhibited *B. mycoides* and *B. subtilis* growth with a MIC value of 0.0008  $\mu$ g/mL and *B. cereus* with a MIC value of 63  $\mu$ g/mL [19, 121]. However, this depsidone was ineffective as an *E. coli* Rec A protein inhibitor [63]. Moreover, salazinic acid showed moderate antifungal activity against *Fusarium udum* (IC<sub>50</sub> value of 88.20  $\mu$ g/mL) [122]. Furthermore, this compound promoted growth effects on probiotic bacteria *Lactobacillus casei* [123].

Salazinic acid has also turned out to be interesting as an antioxidant compound as revealed in different *in vitro* assays (DPPH assay, SOR assay, ORAC assay) [19, 70, 123, 124]. Because of its antioxidant properties, this depsidone increased cell viability and reduced ROS production in a hydrogen peroxide-induced oxidative stress model in the human U373 MG astrocytoma cell line [124]. Moreover, salazinic acid proved to protect against UVA sun-rays (PF-UVA > 2) [70].

Another property attributed to salazinic action is its ability to heal wounds on HaCaT keratinocytes [125].

### Stictic acid

Stictic acid has been investigated for its antioxidant, antimicrobial, and cytotoxic properties. This promising compound showed antioxidant activity in diverse *in vitro* test models. Despite its low DPPH radical scavenging activity (less than 10%), stictic acid exhibited moderate ORAC values (2.32  $\mu$ molTE/mg), high SOR scavenging activity (IC<sub>50</sub> value of 35  $\mu$ M), and good hydroxyl radical scavenging activity (7.63 Trolox equivalents) [91, 124, 126]. Furthermore, in hydrogen peroxide-induced oxidative stress conditions, this depsidone protected human U373 MG astrocytoma cell line at 5, 10, and 25 g/mL concentrations via inhibition of ROS production [124]. These findings showed that stictic acid may be a potential neuroprotective compound.

On the other hand, cytotoxicity evaluation on murine melanocytes B16 cells and human HaCaT keratinocyte cell lines showed no safety; therefore, its possible cosmetic use was dismissed [91].

Enzymes involved in fatty acid biosynthesis processes such as FabZ are excellent targets for developing broad-spectrum antibiotics. Differences between FAS systems (bacterial and human) imply that the inhibition process does not interfere with the host. Stictic acid exhibited a significant inhibitory effect against *Francisella tularensis* (IC<sub>50</sub> value of 13 μM) and *Yersinia pestis* (IC<sub>50</sub> value of 27 μM) β-hydroxyacyl-acyl carrier protein dehydratase (FabZ) [55]. Stictic acid's antimicrobial properties have been investigated, along with other depsidones through *E. coli* RecA protein inhibition. RecA is related to bacterial SOS response regulation, which is involved in resistance to antimicrobials. Stictic acid exhibited low RecA inhibition (16.7%) [63].

*In vitro* and *in silico* assays reported cytotoxic activity of this compound. In human cancer, p53 genes mutate frequently. Using docking studies, stictic acid showed potential p53 reactivation by binding to a transiently open L1/S3 pocket of the p53 core domain [127]. In another study, stictic acid showed great potential as a p53 activator and less adverse effect but poor pharmacokinetic properties [128]. To support *in silico* assays, stictic acid was biologically evaluated in human Saos-2 cells expressing cancer mutant R175H, restoring p53 activity via induction of the cell cycle inhibitor p21 [127]. Moreover, stictic acid displayed cytotoxic activity in different cell lines. In primary cultures of rat hepatocytes, this depsidone showed significant concentration-dependent activation of caspase 3 and an increased percentage of subdiploid nuclei (DNA fragmentation) [18].

### Variolaric acid

While variolaric acid was tested to evaluate its cytotoxic and antimicrobial activity, the viability assays reported no significant effect on human breast adenocarcinoma cell line MCF-7, human cervical adenocarcinoma cell line HeLa, and human colon carcinoma HCT-116 [76]. Moreover, this depsidone had a low capacity to inhibit *E. coli* RecA protein (3.2%) [63].

### Vicanicin

Cytotoxic activity of vicanicin was evaluated in different cell cancer lines, showing significant loss of viability in a concentration-dependent manner on human cervix adenocarcinoma HeLa cell lines and human colon carcinoma HCT-116 (IC<sub>50</sub> values of 67 μM and 40.5 μM, respectively). However, vicanicin did not have effects on human breast adenocarcinoma MCF-7 cells. This depsidone neither exhibited antiradical activity nor reduced intracellular ROS level, dismissing both as the potential mechanism of cytotoxicity [76].

In the model of androgen-sensitive (LNCaP) and androgen-insensitive (DU-145) human prostate cancer cells, vicanicin decreased cell growth by the induction of apoptosis. The expression of Bcl-2, Bax, TRAIL, COX-2, NOS2, and Hsp70 proteins was analyzed, and the inhibition of Hsp70 proteins expression as a mediator of the process should be highlighted [129]. Moreover, this depsidone exhibited moderate activity against HL-60 cells as revealed on antileukemic assay [130]. Regarding its antimicrobial

activity, this depsidone showed moderate inhibition of *E. coli* RecA protein (73%) [63].

## Other Depsidones

Many depsidones have been identified but barely studied. Computational studies have revealed that conorstictic acid, cryptostictic acid, conhyprotocetraric acid, hypoprotocetraric acid, and gangaleoidin, among other depsidones, are potent hydroxyl and superoxide anion radical scavengers in polar environments [131]. Other stictic acid derivatives also displayed antioxidant activities such as peristictic acid and cryptostictic acid that showed weak DPPH radical scavenging activity (about 10%) and potent superoxide anion radical scavenging activity equivalent to that of ascorbic acid. These compounds showed no cytotoxicity on B16 murine melanoma and HaCaT human keratinocyte cell lines (IC<sub>50</sub> higher than 100 μM) [91]. The compounds 8'-O-methylstictic and deoxystictic acid showed radical scavenging activity (61.85 and 13.176 Trolox equivalents, respectively) [126]. Moreover, 8'-O-methylstictic acted as a DPPH scavenger and had good properties for skin penetration (lipophilicity and permeability) [132].

These derivatives have also displayed other activities. For example, hypostictic acid showed antimicrobial properties due to its moderate inhibitory activity against *M. tuberculosis* (MIC value of 94 μg/mL) [93]. The compound 8'-O-ethylstictic presented moderate cytotoxicity against human epithelial carcinoma HeLa, human lung cancer NCI-H460, liver hepatocellular carcinoma HepG2, and human breast cancer MCF-7 cell lines [133].

Other depsidones recently identified, such as ceratinalone and flavicansone, isolated from *Usnea ceratina* Ach. and *Teloschistes flavicans* (Sw.) Norman, respectively, have also shown cytotoxic properties [130, 133]. Ceratinalone has been tested against different cancer cell lines such as human epithelial carcinoma HeLa, human lung cancer NCI-H460, liver hepatocellular carcinoma HepG2, and human breast cancer MCF-7. It acted as a moderate cytotoxic agent [133]. On the other hand, flavicansone exhibited cytotoxic activity as evidenced in an antileukemic assay against HL-60 cells (IC<sub>50</sub> value of 58 μM) [130].

## Conclusions and Future Perspectives

Indeed, lichens produce unique bioactive secondary metabolites such as depsidones. Most pharmacological studies of depsidones focus on fumarprotocetraric acid, lobaric acid, norstictic acid, physodic acid, salazinic acid, and stictic acid compounds. Lichen depsidones have proven their ability to perform diverse biological activities, with cytotoxic, antimicrobial, and antioxidant the most studied. While many published works are on *in vitro* studies, the *in vivo* studies are very limited, and no clinical trials are yet available.

The cytotoxic activity has been evaluated against different cell lines of animal and human origin. Most of these works on cytotoxic activity are based on assessing their effect on cell viability, however, there are fewer studies that clarify the molecular targets and signaling pathways. The most interesting depsidones with cytotoxic activity included lobaric and physodic acids. Regarding the antimicrobial activity, most of the studies evaluated antibacterial

activity against both Gram-positive bacteria and Gram-negative bacteria and fungi, mainly *Candida* spp. Among depsidones, fumarprotocetraric and protocetraric acids are emphasized for their antimicrobial properties. The antioxidant activity has been investigated using techniques such as the DPPH method and ORAC assay as well as in cellular and animal models of oxidative stress. The compounds salazinic acid and stictic acid stand out for their antioxidant properties.

Our study revealed that the future perspectives of pharmacological research on depsidones should focus on:

1. Deepening the activities for these depsidones, clarifying the mechanism of action.
2. Evaluating other and novel potential actions and properties of depsidones.
3. Investigating the potential therapeutic activity of unstudied depsidones from a pharmacological perspective as notatic acid, nortotatic acid, constictic acid, and diploicin.
4. Performing more *in vivo* studies confirming the activity shown in *in vitro* studies.
5. Conducting clinical trials for those depsidones that have shown potential pharmacological activities.

### Contributors' Statement

Data collection: I.M. Ureña-Vacas, E. González-Burgos; drafting the manuscript: I.M. Ureña-Vacas, E. González-Burgos; critical revision of the manuscript: P.K. Divakar, M.P. Gómez-Serranillos.

### Acknowledgements

This study was supported by the Spanish Ministry of Science, Innovation, and Universities (PID2019-105312GB-I00) and the Santander-University Complutense of Madrid (PR87/19-22637). I. Ureña-Vacas is supported by a grant CT42/18-CT43/18 from Complutense University of Madrid for predoctoral research.

### Conflict of Interest

The authors declare that they have no conflict of interest.

### References

- [1] Aschenbrenner IA, Cernava T, Berg G, Grube M. Understanding microbial multi-species symbioses. *Front Microbiol* 2016; 7: 180. doi:10.3389/fmicb.2016.00180
- [2] Calcott MJ, Ackerley DF, Knight A, Keyzers RA, Owen JG. Secondary metabolism in the lichen symbiosis. *Chem Soc Rev* 2018; 47: 1730–1760. doi:10.1039/c7cs00431a
- [3] Ivanova D, Ivanov D. Ethnobotanical use of lichens: lichens for food review. *Scr Sci Med* 2009; 41: 11. doi:10.14748/ssm.v41i1.456
- [4] Singh H, Husain T, Agnihotri P, Pande PC, Khatoon S. An ethnobotanical study of medicinal plants used in sacred groves of Kumaon Himalaya, Uttarakhand, India. *J Ethnopharmacol* 2014; 154: 98–108. doi:10.1016/j.jep.2014.03.026
- [5] Devkota S, Chaudhary R, Werth S, Scheidegger C. Indigenous knowledge and use of lichens by the lichenophilic communities of the Nepal Himalaya. *J Ethnobiol Ethnomed* 2017; 13: 1–10. doi:10.1186/s13002-017-0142-2
- [6] Molnár K, Farkas E. Current results on biological activities of lichen secondary metabolites: A review. *Z Naturforsch C J Biosci* 2010; 65: 157–173. doi:10.1515/znc-2010-3-401
- [7] Furmanek Ł, Czarnota P, Seaward MRD. Antifungal activity of lichen compounds against dermatophytes: a review. *J Appl Microbiol* 2019; 127: 308–325. doi:10.1111/jam.14209
- [8] Rankovic B, Kosanic M. Lichens as a Potential Lichen Source of bioactive secondary Metabolites. In: Rankovic B, ed. *Lichen secondary Metabolites. Bioactive Properties and pharmaceutical Potential*. Cham, Switzerland: Springer International; 2015: 1–26
- [9] Nash TH, Ryan BD, Gries C, Bungartz F. *Lichen Flora of the greater Sonoran Desert Region*. Dexter, MI: Arizona State University, Thomas-shore, Inc.; 2002
- [10] Fernández-Moriano C, Gómez-Serranillos MP, Crespo A. Antioxidant potential of lichen species and their secondary metabolites. A systematic review. *Pharm Biol* 2016; 54: 1–17. doi:10.3109/13880209.2014.1003354
- [11] Solárová Z, Liskova A, Samec M, Kubatka P, Büsselberg D, Solár P. Anticancer potential of lichens' secondary metabolites. *Biomolecules* 2020; 10: 87. doi:10.3390/biom10010087
- [12] Piovano M, Garbarino JA, Giannini FA, Correché ER, Feresin G, Tapia A, Zacchino S, Enriz RD. Evaluation of antifungal and antibacterial activities of aromatic metabolites from lichens. *Bol Soc Chil Quím* 2002; 47: 235–240. doi:10.4067/S0366-16442002000300006
- [13] Podterob A. Chemical composition of lichens and their medical applications. *Pharm Chem J* 2008; 42: 582–588. doi:10.1007/s11094-009-0183-5
- [14] Shukla V, Joshi GP, Rawat MSM. Lichens as a potential natural source of bioactive compounds: A review. *Phytochem Rev* 2010; 9: 303–314. doi:10.1007/s11101-010-9189-6
- [15] Vickery ML, Vickery B. Polyketides. In: *Secondary Plant Metabolism*. London: MacMillan Press; 1981: 88–111
- [16] Legaz M, de Armas R, Vicente C. Bioproduction of Depsidones for pharmaceutical Purposes. In: Rundfeldt C, ed. *Drug Development—A case Study based Insight into modern Strategies*. InTech; 2011. doi:10.5772/27051. Accessed November 1, 2020 at: <http://www.intechopen.com/books/drug-development-a-case-study-based-insight-into-modern-strategies/bioproduction-of-depsidones-for-pharmaceutical-purposes>
- [17] Ibrahim SRM, Mohamed GA, Al Haidari RA, El Kholy AA, Zayed MF, Khayat MT. Biologically active fungal depsidones: chemistry, biosynthesis, structural characterization, and bioactivities. *Fitoterapia* 2018; 129: 317–365. doi:10.1016/j.fitote.2018.04.012
- [18] Correché ER, Enriz RD, Piovano M, Giannini F, Garbarino J, Enriz D. Cytotoxic and apoptotic effects on hepatocytes of secondary metabolites obtained from lichens. *Altern Lab Anim* 2004; 32: 605–615. doi:10.1177/026119290403200611
- [19] Manojlović N, Ranković B, Kosanić M, Vasiljević P, Stanojković T. Chemical composition of three *Parmelia* lichens and antioxidant, antimicrobial and cytotoxic activities of some their major metabolites. *Phytomedicine* 2012; 19: 1166–1172. doi:10.1016/j.phymed.2012.07.012
- [20] Paluszczak J, Kleszcz R, Studzińska-Sroka E, Krajka-Kuźniak V. Lichen-derived caperatic acid and physodic acid inhibit Wnt signaling in colorectal cancer cells. *Mol Cell Biochem* 2018; 441: 109–124. doi:10.1007/s11010-017-3178-7
- [21] Honegger R. Lichen-forming Fungi and their Photobionts. In: Deising HB, ed. *Plant Relationships. The Mycota (A comprehensive Treatise on Fungi as experimental Systems for basic and applied Research)*. Berlin: Springer; 2009: 307–333. doi:10.1007/978-3-540-87407-2\_16
- [22] Brunauer G, Hager A, Grube M, Türk RM, Stocker-Wörgötter E. Alterations in secondary metabolism of aposymbiotically grown mycobionts of *Xanthoria elegans* and cultured resynthesis stages. *Plant Physiol Biochem* 2007; 45: 146–151. doi:10.1016/j.plaphy.2007.01.004



- [23] Elshobary ME, Osman ME, Abo-Shady AM, Komatsu E, Perreault H, Sorensen J, Piercey-Normore MD. Algal carbohydrates affect polyketide synthesis of the lichen-forming fungus *Cladonia rangiferina*. *Mycologia* 2016; 108: 646–656. doi:10.3852/15–263
- [24] Díaz E, Zamora J, Ruibal C, Divakar PK, González-Benítez N, Le Devehat F, Chollet M, Ferron S, Sauvager A, Boustie J, Crespo A, Molina MC. Axenic culture and biosynthesis of secondary compounds in lichen symbiotic fungi, the Parmeliaceae. *Symbiosis* 2020; 82: 1–15. doi:10.1007/s13199-020-00719-3
- [25] Gauslaa Y, Bidussi M, Solhaug KA, Asplund J, Larsson P. Seasonal and spatial variation in carbon based secondary compounds in green algal and cyanobacterial members of the epiphytic lichen genus *Lobaria*. *Phytochemistry* 2013; 94: 91–98. doi:10.1016/j.phytochem.2013.04.003
- [26] Nguyen KH, Chollet-Krugler M, Gouault N, Tomasi S. UV-protectant metabolites from lichens and their symbiotic partners. *Nat Prod Rep* 2013; 30: 1490–1508. doi:10.1039/c3np70064j
- [27] Stocker-Wörgötter E. Biochemical Diversity and Ecology of Lichen-forming Fungi: Lichen Substances, chemosyndromic Variation and Origin of Polyketide-Type Metabolites (biosynthetic Pathways). In: Upreti DK, Divakar PK, Shukla V, Bajpai R, eds. *Recent Advances in Lichenology: Modern Methods and Approaches in Lichen Systematics and Culture Techniques*, Volume 2. New Delhi: Springer; 2015: 161–180. doi:10.1007/978-81-322-2235-4\_9
- [28] Parrot D, Legrave N, Delmail D, Grube M, Suzuki M, Tomasi S. Review – Lichen-associated bacteria as a hot spot of chemodiversity: Focus on unciamycin, a promising compound for future medicinal applications. *Planta Med* 2016; 82: 1143–1152. doi:10.1055/s-0042-105571
- [29] Hawksworth D, Grube M. Lichens redefined as complex ecosystems. *New Phytol* 2020; 227: 1281–1283. doi:10.1111/nph.16630
- [30] Smith H, Dal Grande F, Muggia L, Keuler R, Divakar PK, Grewe F, Schmitt I, Thorsten Lumbsch H, Leavitt SD. Metagenomic data reveal diverse fungal and algal communities associated with the lichen. *Symbiosis* 2020; 82: 133–147. doi:10.1101/2020.03.04.966853
- [31] Mosbach K. Biosynthesis of lichen substances, products of a symbiotic association. *Angew Chem* 1969; 8: 240–250. doi:10.1002/anie.196902401
- [32] Elix JA, Stocker-Wörgötter E. *Biochemistry and secondary Metabolites*. In: Thomas H Nash III, ed. *Lichen Biology*. 2nd ed. Cambridge: Cambridge University Press; 2008: 104–133. doi:10.1017/CBO9780511790478.008
- [33] Huneck S, Yoshimura I. *Identification of Lichen Substances*. Berlin-Heidelberg: Springer; 1996: 493
- [34] Culberson CF. Joint occurrence of a lichen depsidone and its probable depside precursor. *Science* 1964; 143: 255–256. doi:10.1126/science.143.3603.255
- [35] Erdtman GHG. The chemistry of forest, humic acids, lichens, lignans, lignins and conifers. *Tappi* 1962; 45: 14A, 16A, 18A, 20A, 26A, 28A, 30A, 34A, 36A, 38A
- [36] Culberson WL, Culberson CF. The Lichen Genera *Cetrelia* and *Platismatia* (Parmeliaceae). *Systematic Plant Studies. Contributions from the United States National Herbarium*. Washington, DC: Smithsonian Institution Press; 1968: 449–558
- [37] Culberson CF. A note on the chemical strains of *Pseudevernia furfuracea*. *Bryologist* 1965; 68: 435–439
- [38] Elix JA, Jenie UA, Parker JL. A novel synthesis of the lichen depsidones divaronic acid and stenosporonic acid, and the biosynthetic implications. *Aust J Chem* 1987; 40: 1451–1464
- [39] Stocker-Wörgötter E. Metabolic diversity of lichen-forming ascomycetous fungi: culturing, polyketide and shikimate metabolite production, and PKS genes. *Nat Prod Rep* 2008; 25: 188–200. doi:10.1039/b606983p
- [40] Schmitt I, Martín MP, Kautz S, Lumbsch HT. Diversity of non-reducing polyketide synthase genes in the Pertusariales (lichenized Ascomycota): a phylogenetic perspective. *Phytochemistry* 2005; 66: 1241–1253. doi:10.1016/j.phytochem.2005.04.014
- [41] Armaleo D, Sun X, Culberson C. Insights from the first putative biosynthetic gene cluster for a lichen depside and depsidone. *Mycologia* 2011; 103: 741–754. doi:10.3852/10-335
- [42] Bertrand RL, Abdel-Hameed M, Sorensen JL. Lichen biosynthetic gene clusters. Part I. Genome sequencing reveals a rich biosynthetic potential. *J Nat Prod* 2018; 81: 723–731. doi:10.1021/acs.jnatprod.7b00769
- [43] Armaleo D, Müller O, Lutzoni F, Andr sson  S, Blanc G, Bode HB, Collart FR, Dal Grande F, Dietrich F, Grigoriev IV, Joneson S, Kuo A, Larsen PE, Logsdon JM Jr, Lopez D, Martin F, May SP, McDonald TR, Merchant SS, Miao V, Morin E, Oono R, Pellegrini M, Rubinstein N, Sanchez-Puerta MV, Savelkoul E, Schmitt I, Slot JC, Soanes D, Sz v nyi P, Talbot NJ, Veneault-Fourrey C, Xavier BB. The lichen symbiosis re-viewed through the genomes of *Cladonia grayi* and its algal partner *Asterochloris glomerata*. *BMC Genom* 2019; 20: 605. doi:10.1186/s12864-019-5629-x
- [44] Pizarro D, Divakar PK, Grewe F, Crespo A, Dal Grande F, Lumbsch HT. Genome-wide analysis of biosynthetic gene cluster reveals correlated gene loss with absence of usnic acid in lichen-forming fungi. *Genome Biol Evol* 2020; 12: 1858–1868. doi:10.1093/gbe/evaa189
- [45] Hunyadi A. The mechanism(s) of action of antioxidants: From scavenging reactive oxygen/nitrogen species to redox signaling and the generation of bioactive secondary metabolites. *Med Res Rev* 2019; 39: 2505–2533. doi:10.1002/med.21592
- [46] Manojlovic NT, Vasiljevic PJ, Maskovic PZ, Juskovic M, Bogdanovic-Dusanovic G. Chemical composition, antioxidant, and antimicrobial activities of lichen *Umbilicaria cylindrica* (L.) Delise (Umbilicariaceae). *Evid Based Complement Alternat Med* 2012; 2012: 452431. doi:10.1155/2012/452431
- [47] Williams D, Loganzo F, Whitney L, Toggias J, Harrison R, Singh M, McDonald L, Chelvendran S, Andersen R. Depsides isolated from the Sri Lankan lichen *Parmotrema* sp. exhibit selective Plk1 inhibitory activity. *Pharm Biol* 2011; 49: 296–301. doi:10.3109/13880209.2010.517540
- [48] Hong JM, Suh SS, Kim TK, Kim JE, Han SJ, Youn UJ, Yim JH, Kim IC. Anticancer activity of lobaric acid and lobarstin extracted from the antarctic lichen *Stereocaulon alpinum*. *Molecules* 2018; 23: 658. doi:10.3390/molecules23030658
- [49] Huang Z. Bcl-2 family proteins as targets for anticancer drug design. *Oncogene* 2000; 19: 6627–6631. doi:10.1038/sj.onc.1204087
- [50] Emsen B, Ozdemir O, Engin T, Togar B, Cavusoglu S, Turkez H. Inhibition of growth of U87MG human glioblastoma cells by *Usnea longissima* Ach. *An Acad Bras Cienc* 2019; 91: e20180994. doi:10.1590/0001-3765201920180994
- [51] Wisastra R, Dekker FJ. Inflammation, cancer and oxidative lipoygenase activity are intimately linked. *Cancers (Basel)* 2014; 6: 1500–1521. doi:10.3390/cancers6031500
- [52] Ebrahim HY, Elsayed HE, Mohyeldin MM, Akl MR, Bhattacharjee J, Egbert S, El Sayed KA. Norstictic acid inhibits breast cancer cell proliferation, migration, invasion, and *in vivo* invasive growth through targeting c-Met. *Phytother Res* 2016; 30: 557–566. doi:10.1002/ptr.5551
- [53] Zhang Y, Xia M, Jin K, Wang S, Wei H, Fan C, Wu Y, Li X, Li G, Zeng Z, Xiong W. Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities. *Mol Cancer* 2018; 17: 45. doi:10.1186/s12943-018-0796-y
- [54] Alam MK, Alhhazmi A, DeCoteau JF, Luo Y, Geyer CR. RecA inhibitors potentiate antibiotic activity and block evolution of antibiotic resistance. *Cell Chem Biol* 2016; 23: 381–391. doi:10.1016/j.chembiol.2016.02.010
- [55] McGillick BE, Kumaran D, Vieni C, Swaminathan S.  $\beta$ -Hydroxyacyl-acyl carrier protein dehydratase (FabZ) from *Francisella tularensis* and *Yersinia pestis*: structure determination, enzymatic characterization, and cross-inhibition studies. *Biochemistry* 2016; 55: 1091–1099. doi:10.1021/acs.biochem.5b00832



- [56] Feibelman KM, Fuller BP, Li L, LaBarbera DV, Geiss BJ. Identification of small molecule inhibitors of the Chikungunya virus nsP1 RNA capping enzyme. *Antiviral Res* 2018; 154: 124–131. doi:10.1016/j.antiviral.2018.03.013
- [57] Panzhinskiy E, Ren J, Nair S. Pharmacological inhibition of protein tyrosine phosphatase 1B: a promising strategy for the treatment of obesity and type 2 diabetes mellitus. *Curr Med Chem* 2013; 20: 2609–2625. doi:10.2174/0929867311320210001
- [58] Klamann LD, Boss O, Peroni OD, Kim JK, Martino JL, Zabolotny JM, Moghal N, Lubkin M, Kim YB, Sharpe AH, Stricker-Krongrad A, Shulman GI, Neel BG, Kahn BB. Increased energy expenditure, decreased adiposity, and tissue-specific insulin sensitivity in protein-tyrosine phosphatase 1B-deficient mice. *Mol Cell Biol* 2000; 20: 5479–5489. doi:10.1128/mcb.20.15.5479-5489.2000
- [59] Carpentier C, Barbeau X, Azelmat J, Vaillancourt K, Grenier D, Lagüe P, Voyer N. Lobaric acid and pseudodepsidones inhibit NF- $\kappa$ B signaling pathway by activation of PPAR- $\gamma$ . *Bioorg Med Chem* 2018; 26: 5845–5851. doi:10.1016/j.bmc.2018.10.035
- [60] Lee HW, Kim J, Yim JH, Lee HK, Pyo S. Anti-inflammatory activity of lobaric acid via suppressing NF- $\kappa$ B/MAPK pathways or NLRP3 inflammatory activation. *Planta Med* 2019; 85: 302–311. doi:10.1055/a-0777-2420
- [61] Millot M, Tomasi S, Articus K, Rouaud I, Bernard A, Boustie J. Metabolites from the lichen *Ochrolechia parella* growing under two different heliotropic conditions. *J Nat Prod* 2007; 70: 316–318. doi:10.1021/np060561p
- [62] Bellio P, Segatore B, Mancini A, Di Pietro L, Bottoni C, Sabatini A, Brisdelli F, Piovano M, Nicoletti M, Amicosante G, Perilli M, Celenza G. Interaction between lichen secondary metabolites and antibiotics against clinical isolates methicillin-resistant *Staphylococcus aureus* strains. *Phytomedicine* 2015; 22: 223–230. doi:10.1016/j.phymed.2014.12.005
- [63] Bellio P, Di Pietro L, Mancini A, Piovano M, Nicoletti M, Brisdelli F, Tondi D, Cendron L, Franceschini N, Amicosante G, Perilli M, Celenza G. SOS response in bacteria: Inhibitory activity of lichen secondary metabolites against *Escherichia coli* RecA protein. *Phytomedicine* 2017; 29: 11–18. doi:10.1016/j.phymed.2017.04.001
- [64] Yilmaz M, Türk AO, Tay T, Kivanç M. The antimicrobial activity of extracts of the lichen *Cladonia foliacea* and its (–)-usnic acid, atranorin, and fumarprotocetraric acid constituents. *Z Naturforsch C J Biosci* 2004; 59: 249–254. doi:10.1515/znc-2004-3-423
- [65] Ranković B, Misić M, Sukdolak S. Antimicrobial activity of extracts of the lichens *Cladonia furcata*, *Parmelia caperata*, *Parmelia pertusa*, *Hypogymnia physodes* and *Umbilicaria polyphylla*. *Br J Biomed Sci* 2007; 64: 143–148. doi:10.1080/09674845.2007.11732776
- [66] Pompilio A, Pomponio S, Di Vincenzo V, Crocetta V, Nicoletti M, Piovano M, Garbarino JA, Di Bonaventura G. Antimicrobial and antibiofilm activity of secondary metabolites of lichens against methicillin-resistant *Staphylococcus aureus* strains from cystic fibrosis patients. *Future Microbiol* 2013; 8: 281–292. doi:10.2217/fmb.12.142
- [67] Igoli JO, Gray AI, Clements CJ, Kantheti P, Singla RH. Antitrypanosomal activity & docking studies of isolated constituents from the lichen *Cetraria islandica*: possibly multifunctional scaffolds. *Curr Top Med Chem* 2014; 14: 1014–1021. doi:10.2174/1568026614666140324122323
- [68] Fernández-Moriano C, Divakar PK, Crespo A, Gómez-Serranillos MP. *In vitro* neuroprotective potential of lichen metabolite fumarprotocetraric acid via intracellular redox modulation. *Toxicol Appl Pharmacol* 2017; 316: 83–94. doi:10.1016/j.taap.2016.12.020
- [69] de Barros Alves GM, de Sousa Maia MB, de Souza Franco E, Galvão AM, da Silva TG, Gomes RM, Martins MB, da Silva Falcão EP, de Castro CM, da Silva NH. Expectorant and antioxidant activities of purified fumarprotocetraric acid from *Cladonia verticillaris* lichen in mice. *Pulm Pharmacol Ther* 2014; 27: 139–143. doi:10.1016/j.pupt.2013.07.002
- [70] Lohézić-Le Dévéhat F, Legouin B, Couteau C, Boustie J, Coiffard L. Lichenic extracts and metabolites as UV filters. *J Photochem Photobiol B* 2013; 120: 17–28. doi:10.1016/j.jphotobiol.2013.01.009
- [71] Pavlovic V, Stojanovic I, Jadranin M, Vajs V, Djordjević I, Smelcerovic A, Stojanovic G. Effect of four lichen acids isolated from *Hypogymnia physodes* on viability of rat thymocytes. *Food Chem Toxicol* 2013; 51: 160–164. doi:10.1016/j.fct.2012.04.043
- [72] Cetin H, Tufan-Cetin O, Turk AO, Tay T, Candan M, Yanikoglu A, Sumbul H. Larvicidal activity of some secondary lichen metabolites against the mosquito *Culiseta longiareolata* Macquart (Diptera: Culicidae). *Nat Prod Res* 2012; 26: 350–355. doi:10.1080/14786411003774296
- [73] Yilmaz M, Tay T, Kivanç M, Türk H, Türk AO. The antimicrobial activity of extracts of the lichen *Hypogymnia tubulosa* and its 3-hydroxyphysodic acid constituent. *Z Naturforsch C J Biosci* 2005; 60: 35–38. doi:10.1515/znc-2005-1-207
- [74] Ogmundsdóttir HM, Zoëga GM, Gissurarson SR, Ingólfssdóttir K. Anti-proliferative effects of lichen-derived inhibitors of 5-lipoxygenase on malignant cell-lines and mitogen-stimulated lymphocytes. *J Pharm Pharmacol* 1998; 50: 107–115. doi:10.1111/j.2042-7158.1998.tb03312.x
- [75] Bucar F, Schneider I, Ogmundsdóttir H, Ingólfssdóttir K. Anti-proliferative lichen compounds with inhibitory activity on 12(S)-HETE production in human platelets. *Phytomedicine* 2004; 11: 602–606. doi:10.1016/j.phymed.2004.03.004
- [76] Brisdelli F, Perilli M, Sellitri D, Piovano M, Garbarino JA, Nicoletti M, Bozzi A, Amicosante G, Celenza G. Cytotoxic activity and antioxidant capacity of purified lichen metabolites: an *in vitro* study. *Phytother Res* 2013; 27: 431–437. doi:10.1002/ptr.4739
- [77] Haraldsdóttir S, Guolaugsdóttir E, Ingólfssdóttir K, Ogmundsdóttir HM. Anti-proliferative effects of lichen-derived lipoxygenase inhibitors on twelve human cancer cell lines of different tissue origin *in vitro*. *Planta Med* 2004; 70: 1098–1100. doi:10.1055/s-2004-832657
- [78] Morita H, Tsuchiya T, Kishibe K, Noya S, Shiro M, Hirasawaa Y. Antimitotic activity of lobaric acid and a new benzofuran, sakisacaulon A from *Stereocaulon sasakii*. *Bioorg Med Chem Lett* 2009; 19: 3679–3681. doi:10.1016/j.bmcl.2009.03.170
- [79] Ozgencli I, Budak H, Ciftci M, Anar M. Lichen acids may be used as a potential drug for cancer therapy; by inhibiting mitochondrial thioredoxin reductase purified from rat lung. *Anticancer Agents Med Chem* 2018; 18: 1599–1605. doi:10.2174/1871520618666180525095520
- [80] Seo C, Sohn JH, Ahn JS, Yim JH, Lee HK, Oh H. Protein tyrosine phosphatase 1B inhibitory effects of depsidone and pseudodepsidone metabolites from the antarctic lichen *Stereocaulon alpinum*. *Bioorg Med Chem Lett* 2009; 19: 2801–2803. doi:10.1016/j.bmcl.2009.03.108
- [81] Kim TK, Kim JE, Youn UJ, Han SJ, Kim IC, Cho CG, Yim JH. Total syntheses of lobaric acid and its derivatives from the antarctic lichen *Stereocaulon alpinum*. *J Nat Prod* 2018; 81: 1460–1467. doi:10.1021/acs.jnatprod.8b00227
- [82] Joo YA, Chung H, Yoon S, Park JI, Lee JE, Myung CH, Hwang JS. Skin barrier recovery by Protease-Activated Receptor-2 antagonist lobaric acid. *Biomol Ther (Seoul)* 2016; 24: 529–535. doi:10.4062/biomolther.2016.011
- [83] Kwon IS, Yim JH, Lee HK, Pyo S. Lobaric acid inhibits VCAM-1 expression in TNF- $\alpha$ -stimulated vascular smooth muscle cells via modulation of NF- $\kappa$ B and MAPK signaling pathways. *Biomol Ther (Seoul)* 2016; 24: 25–32. doi:10.4062/biomolther.2015.084
- [84] Ingólfssdóttir K, Gissurarson SR, Müller-Jakic B, Breu W, Wagner H. Inhibitory effects of the lichen metabolite lobaric acid on arachidonate metabolism *in vitro*. *Phytomedicine* 1996; 2: 243–246. doi:10.1016/S0944-7113(96)80049-3
- [85] Ingólfssdóttir K, Chung GA, Skúlason VG, Gissurarson SR, Vilhelmsdóttir M. Antimycobacterial activity of lichen metabolites *in vitro*. *Eur J Pharm Sci* 1998; 6: 141–144. doi:10.1016/s0928-0987(97)00078-x

- [86] Vankadari N, Jeyasankar NN, Lopes WJ. Structure of the SARS-CoV-2 Nsp1/5'-untranslated region complex and implications for potential therapeutic targets, a vaccine, and virulence. *J Phys Chem Lett* 2020; 11: 9659–9668. doi:10.1021/acs.jpcclett.0c02818
- [87] Thadhani VM, Choudhary MI, Ali S, Omar I, Siddique H, Karunaratne V. Antioxidant activity of some lichen metabolites. *Nat Prod Res* 2011; 25: 1827–1837. doi:10.1080/14786419.2010.529546
- [88] Gissurarson SR, Sigurdsson SB, Wagner H, Ingolfssdottir K. Effect of lobaric acid on cysteinyl-leukotriene formation and contractile activity of guinea pig *taenia coli*. *J Pharmacol Exp Ther* 1997; 280: 770–773
- [89] Brandão LF, Alcantara GB, Matos Mde F, Bogo D, Freitas Ddos S, Oyama NM, Honda NK. Cytotoxic evaluation of phenolic compounds from lichens against melanoma cells. *Chem Pharm Bull (Tokyo)* 2013; 61: 176–183. doi:10.1248/cpb.c12-00739
- [90] Ranković B, Kosanić M, Stanojković T, Vasiljević P, Manojlović N. Biological activities of *Toninia candida* and *Usnea barbata* together with their norstictic acid and usnic acid constituents. *Int J Mol Sci* 2012; 13: 14707–14722. doi:10.3390/ijms131114707
- [91] Ismed F, Dévéhat FL, Rouaud I, Ferron S, Bakhtiar A, Boustie J. NMR reassignment of stictic acid isolated from a Sumatran lichen *Stereocaulon montagneanum* (Stereocaulaceae) with superoxide anion scavenging activities. *Z Naturforsch C J Biosci* 2017; 72: 55–62. doi:10.1515/znc-2016-0148
- [92] Tay T, Türk AO, Yılmaz M, Türk H, Kivanç M. Evaluation of the antimicrobial activity of the acetone extract of the lichen *Ramalina farinacea* and its (+)-usnic acid, norstictic acid, and protocetraric acid constituents. *Z Naturforsch C J Biosci* 2004; 59: 384–388. doi:10.1515/znc-2004-5-617
- [93] Honda NK, Pavan FR, Coelho RG, de Andrade Leite SR, Micheletti AC, Lopes TI, Misutsu MY, Beatriz A, Brum RL, Leite CQ. Antimycobacterial activity of lichen substances. *Phytomedicine* 2010; 17: 328–332. doi:10.1016/j.phymed.2009.07.018
- [94] Russo A, Piovano M, Lombardo L, Vanella L, Cardile V, Garbarino J. Pannarin inhibits cell growth and induces cell death in human prostate carcinoma DU-145 cells. *Anticancer Drugs* 2006; 17: 1163–1169. doi:10.1097/01.cad.0000236310.66080.ed
- [95] Russo A, Piovano M, Lombardo L, Garbarino J, Cardile V. Lichen metabolites prevent UV light and nitric oxide-mediated plasmid DNA damage and induce apoptosis in human melanoma cells. *Life Sci* 2008; 83: 468–474. doi:10.1016/j.lfs.2008.07.012
- [96] Hidalgo ME, Fernández E, Quilhot W, Lissi EA. Photohemolytic activity of lichen metabolites. *J Photochem Photobiol B* 1993; 21: 37–40. doi:10.1016/1011-1344(93)80161-2
- [97] Celenza G, Segatore B, Setacci D, Bellio P, Brisdelli F, Piovano M, Garbarino JA, Nicoletti M, Perilli M, Amicosante G. *In vitro* antimicrobial activity of pannarin alone and in combination with antibiotics against methicillin-resistant *Staphylococcus aureus* clinical isolates. *Phytomedicine* 2012; 19: 596–602. doi:10.1016/j.phymed.2012.02.010
- [98] Fournet A, Ferreira ME, Rojas de Arias A, Torres de Ortiz S, Inchausti A, Yaluff G, Quilhot W, Fernandez E, Hidalgo ME. Activity of compounds isolated from Chilean lichens against experimental cutaneous leishmaniasis. *Comp Biochem Physiol C Pharmacol Toxicol Endocrinol* 1997; 116: 51–54. doi:10.1016/s0742-8413(96)00127-2
- [99] Fernández E, Reyes A, Hidalgo ME, Quilhot W. Photoprotector capacity of lichen metabolites assessed through the inhibition of the 8-methoxypsoralen photobinding to protein. *J Photochem Photobiol B* 1998; 42: 195–201. doi:10.1016/s1011-1344(98)00070-0
- [100] Cardile V, Graziano ACE, Avola R, Piovano M, Russo A. Potential anticancer activity of lichen secondary metabolite physodic acid. *Chem Biol Interact* 2017; 263: 36–45. doi:10.1016/j.cbi.2016.12.007
- [101] Kosanić M, Manojlović N, Janković S, Stanojković T, Ranković B. *Evernia prunastri* and *Pseudevernia furfuracea* lichens and their major metabolites as antioxidant, antimicrobial and anticancer agents. *Food Chem Toxicol* 2013; 53: 112–118. doi:10.1016/j.fct.2012.11.034
- [102] Studzińska-Sroka E, Piotrowska H, Kucińska M, Murias M, Bylka W. Cytotoxic activity of physodic acid and acetone extract from *Hypogymnia physodes* against breast cancer cell lines. *Pharm Biol* 2016; 54: 2480–2485. doi:10.3109/13880209.2016.1160936
- [103] Emsen B, Aslan A, Togar B, Turkez H. *In vitro* antitumor activities of the lichen compounds olivetoric, physodic and psoromic acid in rat neuron and glioblastoma cells. *Pharm Biol* 2016; 54: 1748–1762. doi:10.3109/13880209.2015.1126620
- [104] Stojanović IZ, Stanković M, Jovanović O, Petrović G, Smelcerović A, Stojanović GS. Effect of *Hypogymnia physodes* extracts and their depsidones on micronucleus distribution in human lymphocytes. *Nat Prod Commun* 2013; 8: 109–112
- [105] Stojanović IZ, Najman S, Jovanović O, Petrović G, Najdanović J, Vasiljević P, Smelcerović A. Effects of depsidones from *Hypogymnia physodes* on HeLa cell viability and growth. *Folia Biol (Praha)* 2014; 60: 89–94
- [106] Talapatra SK, Rath O, Clayton E, Tomasi S, Kozielski F. Depsidones from lichens as natural product inhibitors of M-Phase Phosphoprotein 1, a human kinesin required for cytokinesis. *J Nat Prod* 2016; 79: 1576–1585. doi:10.1021/acs.jnatprod.5b00962
- [107] Bauer J, Waltenberger B, Noha SM, Schuster D, Rollinger JM, Boustie J, Chollet M, Stuppner H, Wenz O. Discovery of depsides and depsidones from lichen as potent inhibitors of microsomal prostaglandin E2 synthase-1 using pharmacophore models. *ChemMedChem* 2012; 7: 2077–2081. doi:10.1002/cmdc.201200345
- [108] Emsen B, Turkez H, Togar B, Aslan A. Evaluation of antioxidant and cytotoxic effects of olivetoric and physodic acid in cultured human amnion fibroblasts. *Hum Exp Toxicol* 2017; 36: 376–385. doi:10.1177/0960327116650012
- [109] Emsen B, Togar B, Turkez H, Aslan A. Effects of two lichen acids isolated from *Pseudevernia furfuracea* (L.) Zopf in cultured human lymphocytes. *Z Naturforsch C J Biosci* 2018; 73: 303–312. doi:10.1515/znc-2017-0209
- [110] Reddy RG, Veeraval L, Maitra S, Chollet-Krugler M, Tomasi S, Dévéhat FL, Boustie J, Chakravarty S. Lichen-derived compounds show potential for central nervous system therapeutics. *Phytomedicine* 2016; 23: 1527–1534. doi:10.1016/j.phymed.2016.08.010
- [111] Osawa T, Kumon H, Reece CA, Shibamoto T. Inhibitory effect of lichen constituents on mutagenicity induced by heterocyclic amines. *Environ Mol Mutagen* 1991; 18: 35–40. doi:10.1002/em.2850180107
- [112] Nishanth KS, Sreerag RS, Deepa I, Mohandas C, Nambisan B. Protocetraric acid: an excellent broad spectrum compound from the lichen *Usnea albopunctata* against medically important microbes. *Nat Prod Res* 2015; 29: 574–577. doi:10.1080/14786419.2014.953500
- [113] Dieu A, Mambu L, Champavier Y, Chaleix V, Sol V, Gloaguen V, Millot M. Antibacterial activity of the lichens *Usnea Florida* and *Flavoparmelia caperata* (Parmeliaceae). *Nat Prod Res* 2020; 34: 3358–3362. doi:10.1080/14786419.2018.1561678
- [114] Deraeve C, Guo Z, Bon RS, Blankenfeldt W, DiLucrezia R, Wolf A, Menninger S, Stigter EA, Wetzel S, Choidas A, Alexandrov K, Waldmann H, Goody RS, Wu YW. Psoromic acid is a selective and covalent Rab-prenylation inhibitor targeting autoinhibited RabGGTase. *J Am Chem Soc* 2012; 134: 7384–7391. doi:10.1021/ja211305j
- [115] Samatov TR, Wolf A, Odenwälder P, Bessonov S, Deraeve C, Bon RS, Waldmann H, Lührmann R. Psoromic acid derivatives: a new family of small-molecule pre-mRNA splicing inhibitors discovered by a stage-specific high-throughput *in vitro* splicing assay. *Chembiochem* 2012; 13: 640–644. doi:10.1002/cbic.201100790
- [116] Hassan STS, Šudomová M, Berchová-Bímová K, Šmejkal K, Echeverría J. Psoromic acid, a lichen-derived molecule, inhibits the replication of HSV-1 and HSV-2, and inactivates HSV-1 DNA polymerase: shedding light on antiherpetic properties. *Molecules* 2019; 24: 2912. doi:10.3390/molecules24162912

- [117] Sweidan A, Chollet-Krugler M, Sauvager A, van de Weghe P, Chokr A, Bonnaure-Mallet M, Tomasi S, Bousarghin L. Antibacterial activities of natural lichen compounds against *Streptococcus gordonii* and *Porphyromonas gingivalis*. *Fitoterapia* 2017; 121: 164–169. doi:10.1016/j.fitote.2017.07.011
- [118] Hassan STS, Šudomová M, Berchová-Bímová K, Gowrishankar S, Rengasamy KRR. Antimycobacterial, enzyme inhibition, and molecular interaction studies of psoromic acid in *Mycobacterium tuberculosis*: efficacy and safety investigations. *J Clin Med* 2018; 7: 226. doi:10.3390/jcm7080226
- [119] Lauinger IL, Vivas L, Perozzo R, Stairiker C, Tarun A, Zloh M, Zhang X, Xu H, Tonge PJ, Franzblau SG, Pham DH, Esguerra CV, Crawford AD, Maes L, Tasdemir D. Potential of lichen secondary metabolites against *Plasmodium* liver stage parasites with FAS-II as the potential target. *J Nat Prod* 2013; 76: 1064–1070. doi:10.1021/np400083k
- [120] Behera BC, Mahadik N, Morey M. Antioxidative and cardiovascular-protective activities of metabolite usnic acid and psoromic acid produced by lichen species *Usnea complanata* under submerged fermentation. *Pharm Biol* 2012; 50: 968–979. doi:10.3109/13880209.2012.654396
- [121] Candan M, Yilmaz M, Tay T, Erdem M, Türk AO. Antimicrobial activity of extracts of the lichen *Parmelia sulcata* and its salazinic acid constituent. *Z Naturforsch C J Biosci* 2007; 62: 619–621. doi:10.1515/znc-2007-7-827
- [122] Goel M, Dureja P, Rani A, Uniyal PL, Laatsch H. Isolation, characterization and antifungal activity of major constituents of the Himalayan lichen *Parmelia reticulata* Tayl. *J Agric Food Chem* 2011; 59: 2299–2307. doi:10.1021/jf1049613
- [123] Gaikwad S, Verma N, Sharma BO, Behera BC. Growth promoting effects of some lichen metabolites on probiotic bacteria. *J Food Sci Technol* 2014; 51: 2624–2631. doi:10.1007/s13197-012-0785-x
- [124] de Paz GA, Raggio J, Gómez-Serranillos MP, Palomino OM, González-Burgos E, Carretero ME, Crespo A. HPLC isolation of antioxidant constituents from *Xanthoparmelia* spp. *J Pharm Biomed Anal* 2010; 53: 165–171. doi:10.1016/j.jpba.2010.04.013
- [125] Burlando B, Ranzato E, Volante A, Appendino G, Pollastro F, Verotta L. Antiproliferative effects on tumor cells and promotion of keratinocyte wound healing by different lichen compounds. *Planta Med* 2009; 75: 607–613. doi:10.1055/s-0029-1185329
- [126] Papadopoulou P, Tzakou O, Vagias C, Kefalas P, Roussis V. Beta-orcinol metabolites from the lichen *Hypotrachyna revoluta*. *Molecules* 2007; 12: 997–1005. doi:10.3390/12050997
- [127] Wassman CD, Baronio R, Demir Ö, Wallentine BD, Chen CK, Hall LV, Salehi F, Lin DW, Chung BP, Hatfield GW, Richard Chamberlin A, Luecke H, Lathrop RH, Kaiser P, Amaro RE. Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53. *Nat Commun* 2013; 4: 1407. doi:10.1038/ncomms2361
- [128] Omar SI, Tuszynski J. Ranking the binding energies of p53 mutant activators and their ADMET properties. *Chem Biol Drug Des* 2015; 86: 163–172. doi:10.1111/cbdd.12480
- [129] Russo A, Caggia S, Piovano M, Garbarino J, Cardile V. Effect of vicanicin and protolichesterinic acid on human prostate cancer cells: role of Hsp70 protein. *Chem Biol Interact* 2012; 195: 1–10. doi:10.1016/j.cbi.2011.10.005
- [130] Sanjaya A, Avidlyandi A, Adfa M, Ninomiya M, Koketsu M. A new depsidone from *Teloschistes flavicans* and the antileukemic activity. *J Oleo Sci* 2020; 69: 1591–1595. doi:10.5650/jos.ess20209
- [131] Bay MV, Nam PC, Quang DT, Mechler A, Hien NK, Hoa NT, Vo QV. Theoretical study on the antioxidant activity of natural depsidones. *ACS Omega* 2020; 5: 7895–7902. doi:10.1021/acsomega.9b04179
- [132] Leal A, Rojas JL, Valencia-Islas NA, Castellanos L. New  $\beta$ -orcinol depsides from *Hypotrachyna caraccensis*, a lichen from the páramo ecosystem and their free radical scavenging activity. *Nat Prod Res* 2018; 32: 1375–1382. doi:10.1080/14786419.2017.1346639
- [133] Bui VM, Duong TH, Chavasiri W, Nguyen KP, Huynh BL. A new depsidone from the lichen *Usnea ceratina*. *Nat Prod Res* 2020. doi:10.1080/14786419.2020.1828405